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SUMMARY 
 
Cell adhesion is a fundamental feature of multi-cellular organisms. It is crucial not 
only for the formation and maintenance of cellular architecture but also for the normal 
biological processes. Cell-cell and cell-extracellular matrix (ECM) adhesions are 
mediated by a large number of cell adhesion molecules (CAMs) which are classified 
into five major families: immunoglobulin (Ig)-like CAMs, integrins, selectins, 
cadherins and heparin sulfate proteoglycans (HSPG).  
 
Previously, a novel gene hepaCAM in liver was identified by Dr. Shen Shali’s group. 
Mapped to human chromosome 11q24, hepaCAM encodes a CAM of the Ig-like 
superfamily. The gene is widely expressed in normal human tissues and is frequently 
silenced in a variety of tumors. Re-expression of hepaCAM in cancer cell lines 
significantly inhibits cell growth. The frequent loss of hepaCAM in human cancers 
and its inhibitory effects on cell growth fulfill two of the most important criteria to 
define tumor suppressors. 
 
The present study aims to further investigate the characteristics of hepaCAM, mainly 
focusing on two subjects: 1) the connection between hepaCAM and the integrin-
dependent signaling, and 2) the proteolytic cleavage of hepaCAM.  
 
Besides the suppressive effects on cell growth, hepaCAM promotes cell-ECM 
adhesion and cell motility. Since integrins play a central role in cell-ECM interactions, 
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it would be interesting to investigate the relationship between hepaCAM and integrins. 
The first study demonstrates that when re-expressed in MCF7 cells, hepaCAM 
accelerates the initial cell attachment and spreading on a fibronectin substrate. Both 
the velocity and directionality of cell migration are also enhanced. In addition, 
hepaCAM is found to be physically associated with integrin β1, the most highly 
expressed integrin in MCF7 cells; moreover, hepaCAM up-regulates the protein 
expression of integrin β1 as well as its active form. Interestingly, hepaCAM regulates 
the assembly of the focal contacts time dependently. The unique regulation allows the 
cells to adhere to the ECM quickly and adapts to a migration mode in an efficient way. 
Furthermore, hepaCAM alters the activity of Rho family GTPases. At last, the altered 
signaling mediated by hepaCAM results in an altered organization of the actin 
cytoskeleton, which supports a migratory phenotype. These results indicate that 
although possessing the properties of a tumor suppressor, given an environment that 
favors cell migration, hepaCAM may work in concert with integrin signaling pathway 
to contribute to a more migratory phenotype in cancer.  
 
Proteolytic cleavage is a common process for many membrane-anchored proteins. In 
the second study, a proteolytic cleavage of hepaCAM is identified. This cleavage 
generates a 25-kD product containing mainly the cytoplasmic domain of hepaCAM. 
The phorbol ester phorbol 12-myristate 13-acetate (PMA) has no effect on hepaCAM 
cleavage. However, the cleavage is promoted by the Ca2+ ionophore ionomycin. In 
addition, inhibitors of proteasome and cysteine proteases strongly suppress the 
cleavage of hepaCAM, indicating the involvement of proteasome, calpain-1 and 
cathepsin B. Furthermore, the cytoplasmic truncated mutant of hepaCAM fails to 
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promote cell-ECM adhesion and migration, and loses the inhibitory effect on cell 
growth, suggesting a regulatory role of the cleavage in hepaCAM functions. 
 
In conclusion, the first study uncovers a novel connection between hepaCAM and the 
integrin-dependent signaling, providing the molecular basis for the hepaCAM-
mediated cell-ECM adhesion and migration. The second study explores the 
mechanisms that are involved in hepaCAM cleavage and sheds light on the possibility 
of hepaCAM cleavage functioning as a regulatory switch. Further explorations are 
needed to better understand hepaCAM and its roles in physiological and pathological 
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CHAPTER 1  INTRODUCTION 
1.1 Cell adhesion molecules 
Cell adhesion is a dynamic process essential for the normal development and 
maintenance of tissues and organs in metazoans (multicellular organisms). 
Accumulating evidences have revealed that cell adhesion is crucial not only for the 
cellular architecture but also for various biological processes including cell migration, 
proliferation and survival (Edelman, 1986). Cell-cell and cell-extracellular matrix 
(ECM) interactions are mediated by a large and complex number of cell adhesion 
molecules (CAMs) expressed on the cell surface that interact with one another in a 
spatially and temporally regulated manner.  
       
It has been more than half a century since the first CAMs were identified. The 
observation of the ability of cells in completely disrupted chick embryo tissues to 
reassemble and reform the original structure suggested the existence of adhesion 
molecules on the cell membrane (Moscona, 1952). Since the pioneering work of 
Moscona, Townes and Holtfreter in the 1950s, significant steps have been made in the 
identification, characterization and classification of several distinct cell adhesion 
systems (Moscona, 1952; Townes and Holtfreter, 1955). These systems allow cells to 
interact dynamically with adjacent cells and the ECM. They are imporant in the 
development, morphogenesis, maintenance and regeneration of the structure and 
organization of organisms (Edelman, 1986; Gumbiner, 1996). They also play 
important roles in pathological conditions such as tumor formation and metastasis 
(Takeichi, 1991).  
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To date, hundreds of CAMs have been identified and characterized. According to 
their structural and functional features, they are classified into five major families: 
immunoglobulin-like CAMs (IgCAMs), integrins, selectins, cadherins and heparin 
sulfate proteoglycans (HSPG).  
 
1.1.1 The immunoglobulin-like CAMs 
IgCAMs belong to the immunoglobulin superfamily, a widespread and complex 
protein family of more than 100 members. IgCAMs function as cell adhesion and 
signaling receptors that transduce extracellular signals from neighbouring cells or the 
ECM to the intracellular signaling machinery. 
 
Structurally, IgCAMs contain one or more Ig-like domains capable of binding to other 
protein motifs (Brummendorf and Rathjen, 1995). Ig-like domains usually contain 
two conserved cysteine residues linked by intrachain disulfide bonds. Structural 
diversity is achieved by post-translational modification of extracellular domains by 
glycosylation, or by modification of intracellular domains through serine, threonine, 
or tyrosine phosphorylation (Brummendorf et al., 1998). Additional variants of some 
IgCAMs are generated by alternative splicing that changes the domain organization.  
 
Certain IgCAMs are expressed in a wide variety of tissues suggesting a general 
biological role (Brummendorf and Rathjen, 1995) while the others show more 
restricted expression patterns consistent with tissue-specific functions. Expression of 
IgCAMs is often regulated during development. The diversity of IgCAMs created by 
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post-translational modification or alternative splicing may also be subjected to 
developmental or tissue-specific regulation (Hassel et al., 1997).  
 
Through their extracellular domains, IgCAMs interact with numerous cell surface 
molecules including other IgCAMs and molecules belonging to different protein 
families. Some IgCAMs, e.g. the L1-like molecules, NCAM, and axonin-1, display 
homophilic binding, i.e. the interaction between two identical molecules. However, 
most IgCAMs interact heterophilically either with non-identical IgCAMs or with 
structurally unrelated partners. IgCAMs expressed by one cell can bind to interaction 
partners on membranes of the opposing cells in trans, or bind laterally to molecules 
on the same membrane plane in cis. The ability of IgCAMs to interact with a large 
variety of molecules suggests its involvement in a complicated network of molecular 
interactions. In addition to the diverse and complex extracellular interactions, the 
cytoplasmic domains of transmembrane IgCAMs also participate in intracellular 
interactions. Thus IgCAMs may play an important role in cell motility. For example, 
the cytoplasmic domains of some IgCAMs are able to bind to components of the 
cortical cytoskeleton like actin and ankyrins (Brummendorf et al., 1998). 
 
IgCAMs also play important roles in signal transductions. Evidences have been 
provided that IgCAMs are associated with different signaling molecules like receptor 
and non-receptor tyrosine kinases, receptor protein tyrosine phophatases (RPTP), and 





Integrins are the major metazoan receptors for cell adhesion to ECM proteins and, in 
vertebrates, also play important roles in certain cell-cell adhesions. Since the 
recognition of the integrin receptor family 24 years ago (Hynes, 1987), they have 
become the best understood cell adhesion receptors. In addition to mediating cell 
adhesion, integrins make transmembrane connections to the cytoskeleton and activate 
numerous intracellular signaling pathways. Integrins and their ligands play key roles 
in development, immune responses, leukocyte traffic, hemostatis, and cancer and are 
at the heart of many human diseases – genetic, autoimmune, and others. They are the 
target of effective therapeutic drugs against thrombsosis and inflammation, and are 
receptors for some viruses and bacteria (Hynes, 2002).  
 
Integrins are restricted to the metazoans; no homologs are detected in prokaryotes, 
plants, or fungi (Whittaker and Hynes, 2002). It is plausible that evolution of integrins 
was necessary to allow the cell-matrix adhesion intrinsic to metazoans (Hynes, 2002). 
In human, integrin family is so far known to comprise 8 β and 18 α subunits, 
assembling into 24 distinct integrin heterodimers. Each of the α and β subunit crosses 
the membrane once, with most of each polypeptide (>1600 amino acids in total) in the 
extracellular space and two short cytoplasmic domains (20-50 amino acids). Each of 
the 24 heterodimers appears to have specific, nonredundant function which is evident 





Cell-cell and cell-ECM adhesions are mediated by the binding of integirn 
extracellular domains to diverse protein ligands; in addition, integrins serve as 
transmembrane mechanical links from those extracellular contacts to the cytoskeleton 
inside cells. For all integrins except α6β4, the linkage is to the actin-based 
microfilament system, which integrins also regulate and modulate. The β4 subunit 
differs from all the others; its cytoplasmic domain is much longer, about 1000 amino 
acids long instead of around 50, making connections to intermediate filaments instead 
of to actin (Hynes, 2002). In part related to the integrin-mediated assembly of 
cytoskeletal linkages, ligation of integrins also triggers a large variety of signal 
transduction events that serve to modulate many aspects of cell behavior including 
proliferation, survival/apoptosis, shape, polarity, motility, gene expression, and 
differentiation. These signal transduction pathways are complex, like those emanating 
from receptors for soluble factors (e.g. G protein-coupled and kinase receptors). In 
fact, many cellular responses to soluble growth factors, such as EGF, PDGF, LPA, 
and thrombin, etc., are dependent on the cell’s being adherent to a substrate via 
integrins. That is the essence of anchorage dependence of cell survival and 
proliferation and integrins lie at the basis of these phenomena (Schwartz and Assoian, 
2001; Frisch and Screaton, 2001).  
 
One important mechanism by which integrin function is regulated is through tight 
spatial and temporal control of integrin affinity for extracellular ligands. This is 
achieved by rapid, reversible changes in the conformation of the extracellular domains 
of the integrin heterodimer, so-called integrin activation (Woodside et al., 2001). 
Despite significant recent advances, the exact nature of the conformational changes 
leading to integrin activation remains controversial. Additional affinity-independent 
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mechanisms, such as integrin clustering, lateral diffusion of receptors, interactions 
with and reorganization of the cytoskeleton, and changes in integrin expression 
patterns also contribute to the control of integrin-mediated adhesion (Laudanna et al., 
2002; van Kooyk and Figdor, 2000; Hogg et al., 2002). Affinity-dependent and –
independent mechanisms are not mutually exclusive and can act in concert; indeed, 
integrin activation and clustering may be mechanistically linked such that activation, 
in combination with ligand occupancy, also stimulates clustering (Erb et al., 1997; Li 
et al., 2002). It has been widely accepted that the membrane-proximal regions of the 
short α and β integrin cytoplasmic tails are well conserved and play crucial roles in 
integrin activation, probably by interacting with one another to stabilize an inactive 
conformation. The more distal region of the β tails regulate activation through 
interactions with signaling proteins that might disrupt the membrane-proximal 
interaction, whereas membrane-distal α sequences regulate β tail conformation and 
association with activator proteins in a cell-type-specific manner (Ylanne et al., 1993). 
Several studies indicate that talin, a major cytoskeletal actin-binding protein that binds 
to integrin tails and colocalize with activated integrins (Critchley 2000), plays a 
crucial role in integrin activation (Tadokoro et al., 2003). Studies also showed that at 
least two other β tail-binding proteins, β3-endoexin (Kashiwagi et al., 1997) and 
cytohesin (Kolanus et al., 1996), and one α tail-binding protein, calcium- and integrin-
binding protein (CIB) (Tsuboi, 2002), might also directly activate integrins.  
 
1.1.3 Cadherins 
Cadherins (named for “calcium-dependent adhesion”) are a superfamily of type-1 
transmembrane proteins important for cell-cell adhesion. Their functions are 
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dependent on calcium ions, hence their name. The cadherin superfamily includes 
classical cadherins, protocadherins, desmogleins, desmocollins, etc (Hulpiau and van 
Roy, 2009). The classical cadherins are single-span transmembrane proteins located 
primarily within adherens junctions, mediating calcium-dependent cell-cell adhesion 
through their five extracellular calcium binding repeats. E-cadherin and N-cadherin 
have been the best characterized and studied. Their intracellular regions link them 
with their cytoplasmic partners β-catenin or plakoglobin and consequently to α-
catenin and the actin filament network (Yap et al., 1997a, b). The desmosomal 
cadherins are the transmembrane protein components of desmosomes, which are sites 
of cell-cell adhesion present particularly in tissues subjected to mechanical strains (e.g. 
epithelia, particularly epidermis, and the myocardium). There are two subfamilies of 
desmosomal cadherins, the desmocollin and desmoglein  proteins, and each possesses 
three subtypes which are expressed in a cell-type and differentiation-specific manner 
(King et al., 1997).  
 
1.1.4 Selectins 
Selectins are single-chain transmembrane glycoproteins that share similar properties 
to C-type lectins due to a related amino terminus and calcium dependent binding. 
Selectins bind to sugar moieties and so are considered to be a type of lectin, cell 
adhesion proteins that bind sugar polymers. Selectins were firstly cloned in 1989. The 
main types include E-selectin, P-selectin, and L-selectin (Kansas, 1996).   
 
L-selectin is expressed on leukocytes (Kansas et al., 1985; Lewinsohn et al., 1987). It 
is rapidly lost from the surface of normal leukocytes in response to a variety of stimuli. 
7 
 
Soluble L-selectin can be detected in the serum of normal healthy individuals at high 
concentrations (Schleiffenbaum et al., 1992). The mechanism of shedding is not 
completely understood, but is clearly the result of proteolytic cleavage at a site just 
outside the plasma membrane. E-selectin expression is limited to endothelium, and 
principally to endothelium in response to inflammatory stimuli (Bevilacqua MP, et al., 
1989). The loss of E-selectin from the surface of activated endothelial cells is caused 
by several factors. First, the half-life of E-selectin mRNA is short. In addition, E-
selectin is rapidly internalized and degraded in lysosomes (Subramaniam et al., 1993). 
The combination of these processes collectively ensures that the expression of E-
selectin at the surface of cytokine-stimulated endothelium is transient. P-selectin 
expression on both endothelium and platelets is also inducible. However, P-selectin is 
stored preformed in the α-granules and Weibel-Palade bodies of platelets and 
endothelium (McEver et al., 1989). P-selectin is rapidly expressed at the cell surface 
as a result of fusion of these granules with the plasma membrane. The sorting of P-
selectin into these granules is controlled by sequences within the cytoplasmic tail. P-
selectin expressed at the cell surface is rapidly internalized, which accounts for its 
transient appearance at the surface of activated endothelium and platelets, and this 
activity also maps to the cytoplasmic tail (Green et al., 1994).  
 
1.1.5 Heparan sulfate proteoglycan 
Heparin sulfate (HS) is a linear polysaccharide found in all animal tissues. It occurs as 
a proteoglycan (PG) in which two or three HS chains are attached in close proximity 
to cell surface or ECM proteins. HS binds to a variety of protein ligands and regulates 
a wide variety of biological activities, including developmental processes, 
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angiogenesis, blood coagulation and tumour metastasis. The major cell membrane 
HSPGs are the transmembrane syndecans (Rapraeger, 1983) and the 
glycosylphosphatidylinositol anchored glypicans. Other minor forms of membrane 
HSPGs include betaglycan and the V-3 isoform of CD44 present on keratinocytes and 
activated monocytes. Cell surface HS sequesters secreted soluble ligands and 
modulates their activity. As coreceptors, HSPGs modulate ligand-receptor encounters 
that can activate and inhibit cell proliferation, motility, and differentiation. As 
receptors, HSPGs regulate internalization and clearance of their ligands via both 
clathrin-coated pits and membrane lipid rafts associated with caveolae.  
 
1.2 Proteolytic cleavage of CAMs 
Of membrane-anchored proteins, approximately 1% undergo regulated protelytic 
cleavage near the plasma membrane, resulting in truncated extracellular or 
intracellular segments in a process known as shedding (Hooper et al., 1997; Werb 
1997). These functionally diverse proteins include CAMs, cytokines, growth factors, 
their receptors and enzymes. Shedding of receptors or coreceptors, like syndecans, 
can produce agonists or antagonists that regulate their ligands’ activities, render cells 
less responsive to their ligands, or potentially generate an active fragment that 
remains membrane-associated or becomes intracellular. Other examples include the 
cleavage of CD44, which plays a critical role in cancer cell migration and metastasis 
and various physiological events (Okamoto et al., 2001); proteolysis of E-cadherin 
regulates epithelial cell-cell adhesion, migration, and ß-catenin translocation 
(Maretzky et al., 2005a); cleavage of the neural adhesion molecule L1 regulates 
neural cell adhesion, migration and neurite outgrowth (Maretzky er al., 2005b).  
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 The shedding process of CAMs is usually differentially regulated by multiple 
pathways. It has been shown that CD44 cleavage is under the control of protein kinase 
C (PKC), Ca2+ influx, Rho GTPase proteins (Okamoto et al., 1999), membrane-type 1 
matrix metalloprotease (Kajita et al., 2001), and γ-secretase (Pelletier et al., 2006). E-
cadherin cleavage is promoted by Ca2+ influx (Ito et al., 1999) and regulated by γ-
secretase (Marambaud et al., 2002) and a disintegrin and metalloprotease 10 
(ADAM10) (Maretzky et al., 2005a). L1 is processed by ADAM10, ADAM17, and γ 
-secretase (Maretzky et al., 2005b). 
 
1.3 Types of cell adhesion 
 
1.3.1 Cell-cell adhesions 
1.3.1.1 Gap junctions  
A gap junction or nexus is a specialized intercellular connection between cells of 
multi-cellular animals (White and Paul, 1999). It directly connects the cytoplasm of 
two cells, which allows various molecules and ions to pass freely between cells 
(Lampe et al., 2004). One gap junction channel is composed of two connexons (or 
hemichannesl) which connect across the intercellular space (Maeda et al., 2009). At 
gap junctions, the intercellular space is 4 nm (Maeda et al., 2009) and unit connexons 
in the membrane of each cell are lined up with one another (Perkins et al., 1998). 
There are four levels of organization of a gap junction: 1) one connexin protein is 
composed of four transmembrane domains; 2) six connexins form one connexon 
10 
 
(hemichannel); 3) two hemichannels that joined together across a cell membrane 
comprise a gap junction channel. A gap junction channel is homotypic when it is 
formed by two identical connexons and heterotypic when it is composed of one 
homomeric and one heteromeric connexon. Two heteromeric connexons also form 
heteromeric gap junction channel; 4) finally, several gap junction channels (can be 
hundreds) assemble into a macromolecular complex called a gap junction. Gap 
junctions allow direct electrical and chemical communication between cells. 
Moreover, molecules smaller than 1000 Daltons are generally allowed to pass through. 
Large biomolecules, e.g. nucleic acid and protein, are precluded from cytoplasmic 
transfer between cells. These properties ensure that molecules and current passing 
through the gap junctions do not leak into the intercellular space.  
 
1.3.1.2 Adherens junctions 
Adherens junctions (AJs) link cell membrane and cytoskeletal components at discrete 
contact regions. The most well known example of AJ is the zonular adherens junction, 
or zonular adherens of polarized epithelial cells. While the zonula adherens is 
continuous or “belt-like” in most epithelia, AJs are often “spot-like”. Spot-like 
junctions may favor anchoring, while a zonular “belt-like” junction enables 
coordination of epithelial sheet movements.  
 
AJs consist of two basic adhesive units: the cadherin/catenin and nectin/afadin 
complexes. The cadherin cytoplasmic domain mediates key structural and signaling 
activities required for adhesion through its association with three distinct proteins 
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known as catenins (Ozawa et al., 1989). β-catenin is an arm-repeat protein (Coates et 
al., 2003) whose direct binding to cadherin is crucial for full adhesive function. α-
catenin is a vinculin homologue that can bind F-actin in vitro (Rimm et al., 1995), and 
is crucial for actin polymerization at or near AJs in vivo. Cadherins also associate with 
p120ctn, which belongs to a subfamily of armadillo proteins (Alema and Salvatore, 
2007). Nectin is a member of the IgG superfamily of calcium-independent adhesion 
molecules. The nectin subfamily contains an extracellular domain comprised of three 
IgG-like loops, and a cytoplasmic domain, which contains a C-terminal PDZ-binding 
motif in most variants (Irie et al., 2004). Nectins form lateral homodimers that can 
engage in both homophilic and heterophilic adhesion with other nectins or nectin-like 
receptors. The cytoplasmic domain of nectin interacts with an actin-binding protein 
known as AF6/afadin (Zhadanov et al., 1999), thereby providing an alternate way to 
couple AJs to actin. Thus, like the cadherin/catenin adhesive unit, the nectin-afadin 
complex contains components that can mediate intercellular adhesion and actin 
association. Besides mediating the basic adhesiveness of cells, AJs also serve 
functions such as contact mediated growth inhibition, invaginations, and 
establishment of apical-basolateral polarity (Nejsum and Nelson, 2007). 
 
1.3.1.3 Desmosomes 
The desmosomes are adhesive intercellular junctions that are crucial to tissues that 
experience mechanical stress, such as the myocardium, bladder, gastrointestinal 
mucosa, and skin (Holthofer et al., 2007). Desmogleins and desmocollins (Garrod 
andn Chidgey, 2008), members of the cadherin superfamily, mediate adhesion at 
desmosomes. The desmogleins and desmocollins both contain four extracellular 
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cadherin homology repeats and a fifth domain termed the extracellular anchor. 
Desmosomes show Ca2+-dependent assembly and adhesion. Classical cadherins 
typically show homophilic interactions, which support cell-cell adhesion and tissue 
patterning. Most studies to date suggest that both desmocollins and desmogleins are 
required for strong cell-cell interactions (Marcozzi et al., 1998; Getsios et al., 2004). 
However, it remains unclear whether homophilic or heterophilic interactions are 
primarily responsible for desmosome adhesion. In the desmosome, the cytoplasmic 
associations with the cadherins are partly mediated by the armadillo family proteins, 
plakoglobin, and the plakophilins. The armadillo proteins include β-catenin, 
plakoglobin (γ-catenin), p120-catenin, p0071, ARVC, δ-catenin, and the plakophilins 
1–3 (Hatzfeld, 2005; Hatzfeld, 2007). The desmosomal cadherins show complex 
developmental and differentiation patterns of expression (Holthofer et al., 2007). 
They play important roles in epithelial proliferation and differentiation, and in the 
robust cell-cell adhesion that is required for tissue integrity. Desmosomal cadherins 
are implicated in human diseases, particularly in disorders affecting the heart and the 
skin. In addition to inherited disorders, desmosomal cadherins are also targets of 
autoimmune disease such as pemphigus.  
 
1.3.1.4 Tight junctions 
Tight junctions (TJs) regulate the passage of ions and molecules through the 
paracellular pathway in epithelial and endotheial cells (Lopez-Bayghen et al., 2005). 
These structures are located at the limit between the apical membrane facing the 
lumen and the basolateral surface in contact with the interior of the organism. The 
barrier function of TJs allows this structure to regulate by size and charge the transit 
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of ions and molecules through the paracellular route (Anderson and Cereijido, 2001). 
Besides functioning as a barrier, TJs work as a fence that limits the free movement of 
lipids and proteins within the plasma membrane between the apical and the basal 
surface (Mandel et al., 1993).  
 
TJs are multiprotein complexes composed of integral proteins that associate with 
cytoplasmic plaque proteins. The former mediate cell-cell adhesion, while the latter 
function as bridge between the TJ and the actin cytoskeleton (Schneeberger and 
Lynch, 2004). The main molecular constituents of TJ include zona occludens (ZO) 
proteins, claudins and occludin. ZOs are peripherally associated membrane proteins. 
These proteins interact together and anchor membrane proteins like claudins, 
occluding and juncional adhesion molecules (JAMs) to the actin cytoskeleton. ZO 
proteins are scaffolds that establish numerous protein-protein interactions that cluster 
at the TJ diverse kinase, phosphatases, small G proteins and nuclear and transcription 
factors (Lopez-Bayghen et al., 2005). Claudins constitute a family of more than 20 
proteins with four transmembrane domains (Morita et al., 1999). They have two 
extracellular loops that display variability in the distribution and number of charged 
residues. This feature is crucial as it determines the paracellular ionic selectivity of the 
TJ. Occludin is present in the filaments that constitute TJs and its overexpression or 
mutation severely affect transepithelial electrical resistance (McCarthy et al., 1996), 
yet occludin knock-out mice are viable and exhibit TJs with an apparent normal 





1.3.2 Cell-extraceullar matrix adhesion  
1.3.2.1 Extracellular matrix  
The ECM is a complex structural entity surrounding and supporting cells that are 
found within mammalian tissues. The ECM is often referred to as the connective 
tissue. The ECM is composed of 4 major classes of molecules: 1) structural proteins, 
e.g. collagen and elastin; 2) specialized proteins, e.g. fibrillin, fibronectin, and laminin; 
3) PGs: these are composed of a protein core to which is attached long chains of 
repeating disaccharide units termed of glycosaminoglycans forming extremely 
complex high molecular weight components of the ECM; 4) non-PG polysaccharide, 
e.g. hyaluronan.  
 
1.3.2.2 Cell-matrix adhesion complexes 
Cell-matrix adhesion complexes (CMACs) mechanically link the cell to the ECM 
(Delon and Brown, 2007). CMACs form upon integrin ligation to the ECM and 
subsequent integrin clustering. This rapidly induces the recruitment of an array of 
CMAC signaling and adaptor proteins, forming large intracellular protein complexes 
bound both to clustered integrin cytoplasmic tails and to actin microfilaments. 
CMACs fulfill a variety of functions in the cell. Besides physically attaching cells to 
the ECM, CMACs also play important roles in the creation, mediation and sensing of 
tension (Geiger and Bershadsky, 2001). In addition, CMACs are influential signaling 
hubs that detect, coordinate, transmit, adapt to and generate various signals regulating 




CMACs differ significantly in features such as size, shape, location, components, 
dynamics and linkage to F-actin. Based on this, CMACs have been divided into a 
number of different categories (Zamir et al., 1999). Most of these CMAC categories 
represent different adhesion maturation states, including: focal points or nascent 
adhesions - small, often newly formed CMACs in the cellular periphery that link to an 
F-actin meshwork; focal compexes (FXs) - mid-sized stationary contact sites linked to 
the cortical actin and/or the actin meshwork within lamellipodia; focal adhesions (FAs) 
– large adhesion sites that elongate along the axis of force application by actin stress 
fibers to which they connect; fibrillar adhesions – elongated adhesions that connect 
microfilament stress fibers with extracellular fibronectin fibers; and podosomes – 
invasive ring structures composed of adhesion machinery and filamentous actin.  
 
The main components of CMACs include integrins, adaptor and signaling proteins, 
and microfilament structures. CMAC components function either as adaptors or as 
signaling molecules, or both. Adaptors may form physical links between, and/or may 
act as scaffolds for signaling molecules. For example talin, which serves as a physical 
link between integrins and F-actin, is a scaffold coordinating other CMAC 
components such as vinculin and PIPKIγ (Ling et al, 2006), and may be involved in 
transduction of tension signaling (Critchley, 2004). Likewise, while focal adhesion 
kinase (FAK) displays inherent kinase activity, the main functions of FAK appear to 
be connected to its capacity as a signaling scaffold (Schlaepfer, 1999). Other 
important examples of CMAC components include paxllin, a highly regulated and 
dynamic scaffold protein; kindlins, which may associate with integrins and form a 
link to actin via migfillin and filamin (Wu, 2005), and act as activators of integrins. 





functions to regulate gene transcription and cell-cell adhesion (Legate et al., 2006); 
zyxin, which incorporates into CMACs in a tension-dependent manner (Zaidel-Bar et 
al, 2004); p130Cas, which may serve as a transducer of both chemical and mechanical 
signaling (Defilippi et al., 2006); c-Src, a key modifier of many CMAC scaffolds, 
such as paxillin and FAK, allowing them to transmit signaling further (Frame et al., 
2002); and various regulators of small GTPase signaling, including the α- and β-PIX 
guanine nucleotide exchange factors (GEFs) (Rosenberger and Kutsche, 2006). The 
actin microfilament system structure and dynamics are to a large extent regulated by 
CMACs and their signaling, and the tension created jointly by the CMACs and 
microfilaments affects both structures. Different dynamic microfilament structures are 
physically linked to CMACs, and each is connected to distinct types of CMACs. 
These microfilament structures include lamellipodia, filopodia, stress fibers and 
podosomes (Spinardi and Marchisio, 2006).  
 
In general, cell-ECM adhesion promotes integrin clustering and recruitment of 
integrin-associated proteins to integrin-rich adhesion sites (Fig. 1-1). One important 
event in this process is cell adhesion-dependent phosphorylation of key focal adhesion 
proteins such as FAK (Parsons, 2003). Phosphorylation of FAK at Tyr-397 creates a 
docking site for the SH2 domain of Src family kinases. Binding of Src to FAK 
phosphor-Tyr-397 site releases an autoinhibitory interaction and consequently 
activates Src. Activated FAK/Src complex in turn phosphorylates components of FAs 
including FAK, paxillin and p130Cas, resulting in recruitment of additional signaling 
intermediates and activation of downstream signaling pathways. A second important 
event is the recruitment of key protein complexes such as the pinch-ILK-parvin 
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and p130Cas, resulting in recruitment and activation of additional signaling 
intermediates including the Rho family GTPases, leading to various cellular changes.
Figure adapted from 
https://www.qiagen.com/geneglobe/pathwayview.aspx?pathwayID=254
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 physical connection between integrins and the actin cytoskeleton. The third important 
event is the changes of the conformation of certain FA proteins in response to 
physical forces exerted on FA. For example it has been shown that the conformation 
and tyrosine phosphorylation of p130Cas are changed in vitro as well as in cells in 
response to mechanical stretches (Sawada et al., 2006).   
 
1.3.2.3 Hemidesmosomes 
Hemidesmosomes (HD) are rivet-like structures on the inner basal surface of 
keratinocytes in the epidermis of skin. They are similar in form to desmosomes when 
visualized by electron microscopy (Nguyen et al., 2006). While desmosomes link two 
cells together, HDs attach one cell to the ECM. Rather than using cadherins, HDs use 
integrins. The HD comprises two rivet-like plaques (the inner and outer plaques); 
together with the anchoring fibrils and anchoring filaments these are collectively 
termed the HD-stable adhesion complex or HD-anchoring filament complex. Together, 
the HD-anchoring filament complex forms a continuous structural link between the 
basal keratinocyte keratin intermediate filaments and the underlying basement 
membrane zone and dermal components. An example configuration of an HD consists 
of cytosolic keratin, non-covalently bonded to a cytosolic plectin plaque, which is 
bonded to a single-pass transmembrane adhesion molecule such as the α6β4 integrin 






1.3.2.4 Dystroglycan complex 
Dystroglycan was originally isolated from skeletal muscle as an integral membrane 
component of the dystrophin-glycoprotein complex (DGC) (Ervasti et al., 1990). In 
vertebrates dystroglycan is composed of α- and β-subunits encoded by a single gene 
and cleaved into two proteins by posttranslational processing (Ibraghimov-
Beskrovnaya et al., 1992). At the sarcolemma, β-dystroglycan binds intracellularly to 
dystrophin, which binds to the actin cytoskeleton, and extracellularly to α-
dystroglycan, a highly glycosylated peripheral membrane protein. It completes the 
link from the cytoskeleton to the basal lamina by binding to ECM proteins containing 
LamG domains, such as laminin, neurexin, agrin, and perlecan. In addition to 
dystroglycan and dystrophin, the DGC in muscle cells contains the sarcoglycan 
complex composed of five sarcoglycan proteins (α, β, γ, δ, ζ) and sarcospan (Wheeler 
and McNally, 2003). Via dystrophin, the sarcolemmal DGC interacts with a pair of 
syntrophins (α1 and β1) and α-dystrobrevin within the cytosol (Peters et al., 1997; 
Sadoulet-Puccio et al., 1997). Though the exact function of the DGC is not entirely 
understood, it is thought to contribute to the structural stability of the muscle cell 
membrane during cycles of contraction and relaxation, thereby protecting the muscle 
from stress-induced membrane damage (Campbell, 1995). In humans, mutations in 
dystrophin cause Duchenne and Becker muscular dystrophy; mutations in 
sarcoglycans cause limb-girdle muscular dystrophy; and mutations in laminin α2 






1.4 Cell migration 
1.4.1 The migration cycle 
Cell migration can be conceptualized as a cyclic process (Lauffenburger and Horwitz, 
1996). The initial response of a cell to a migration-promoting agent is to polarize and 
extend protrusions in the direction of migration. These protrusions can be large, broad 
lamellipodia or sipe-like filopodia, are usually driven by actin polymerization, and are 
stabilized by adhering to the ECM or adjacent cells via transmembrane receptors 
linked to the actin cytoskeleton. These adhesions serve as traction sites for migration 
as the cell moves forward over them, and they are disassembled at the cell rear, 
allowing it to detach (Ridley et al., 2003).  
 
A cell’s migratory behavior depends on its environment. Somatic cells migrating in 
vivo, for example, show large single protrusions and highly directed migration, in 
contrast to the multiple small protrusions they display one planar substrates; cancer 
cells can modify their morphology and nature of migration in response to 
environmental changes (Knight et al., 2000; Friedl and Wolf, 2003). 
 
1.4.2 The protrusive machinery 
Actin filaments are intrinsically polarized with fast-growing “barbed” ends and slow-
growing “pointed” ends, and this inherent polarity is used to drive membrane 
protrusion. However, the organization of filaments depends on the type of protrusion: 
in lamellipodia, actin filaments form a branching “dendritic” network, whereas in 
filopodia they are organized into long parallel bundles. Actin polymerization in 
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lamellipodia is mediated by the Arp2/3 complex, which binds to the sides or tip of a 
pre-existing actin filament and induces the formation of a new daughter filament that 
branches off the mother filament (Welch and Mullins, 2000; Pollard and Borisy, 
2003). Several actin-binding proteins regulate the rate and organization of actin 
polymerization in protrusions by affecting the pool of available monomers and free 
end (Pollard and Borisy, 2003; dos Remedios et al., 2003). For example, profilin 
prevents self-nucleation by binding to actin monomers and also serves to selectively 
target monomers to barbed ends. Filament elongation is terminated by capping 
proteins, thereby restricting polymerization to new filaments close to the plasma 
membrane. In addition, disassembly of older filaments, which is needed to generate 
actin monomers for polymerization at the front end, is assisted by proteins of the 
ADF/cofilin family, which sever filaments and promote actin dissociation from the 
pointed end.  
 
Filopodial protrusion is thought to occur by a filament treadmilling mechanism, in 
which actin filaments within a bundle elongate at their barbed ends and release actin 
monomers from their pointed ends (Welch and Mullins, 2000). The long and 
unbranched filament organization is consistent with assembly occurring by elongation 
rather than by branched nucleation. Many proteins are enriched at filopodial tips, 
including Ena/VASP proteins, which bind barbed ends of actin filaments and 
antagonize both capping and branching, thereby allowing continuous elongation of 
filaments and fascin, which bundles actin filaments and might thereby generate the 
stiffness needed to allow efficient pushing of the plasma membrane in filopodia 
(Welch and Mullins, 2000).  
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The supramolecular design of lamellipodia and filopodia endows them with the 
capacity to perform distinct functions. Biophysical considerations suggest that the 
dendritic organization of lamellipodia provides a tight brush-like structure that is able 
to push along a broad length of plasma membrane (Pollard and Borisy, 2003). 
Through localized activation of the Arp2/3 complex, the lamellipodium could be 
induced to grow in a particular direction, providing the basis for directional migration. 
In contrast, filopodia, with their parallel bundle organization, are particularly well 
designed to serve as sensors and to explore the local environment, although they are 
not essential for chemotaxis.  
 
1.4.3 Rho family GTPases 
The Rho family small guanosine triphosphate (GTP)-binding proteins (GTPases) are 
pivotal regulators of actin and adhesion organization and control the formation of 
lamellipodia and filopodia. They are conformationally regulated by the binding of 
GTP and guanosin diphosphate (GDP): when bound to GTP, they are active and 
interact with their downstream target proteins, which include protein kinases, lipid-
modifying enzymes, and activators of the Arp2/3 complex (Etienne-Manneville and 
Hall, 2002). Rho GTPases are activated by GEFs and inactivated by GTPase 
activation proteins (GAPs) (Moon and Zheng, 2003; Zheng, 2001). Once activated, 
Rho GTPases interact with cellular target proteins (effectors) to generate a 
downstream response. To date, more than 40 effectors, 50 GEFs and 40 GAPs have 




Rac and Cdc42 are both required at the front of migrating cells. The primary role of 
Rac is to generate a protrusive force through the localized polymerization of actin. 
Cdc42 induces actin polymerization to generate filopodia often seen at the front of 
migrating cells (Nobes and Hall, 1995). Cdc42 also plays a crucial role in controlling 
the direction of migration. The Ser/Thr kinase p65PAK is commonly activated upon 
either Rac or Cdc42 activation and is believed to play an important role in regulating 
actin dynamics and cell adhesion during migration. p65PAK regulates FA turnover, 
with the help of PIX and GIT1, and phosphorylates and activates LIM kinase, which 
in turn phosphorylates and inactivates cofilin (Arber et al., 1998). Cdc42 also 
activates WASp and N-WASp directly (Rohatgi et al., 1999, 2000). Rac activates the 
Scar/WAVE family indirectly and this involves an Nck-adaptor complex (Eden et al., 
2002). 
 
Rho activity in migrating cells is associated with FA assembly and cell contractility 
and is responsible for cell body contraction and rear end retraction. One important 
Rho target involved in stimulating actin:myosin filament assembly and therefore 
contractility is the Ser/Thr kinase p160ROCK. p160ROCK, like p65PAK, can 
phosphorylate and activate LIMK, which in turn phosphorylates and inactivates 
cofilin leading to stabilization of actin filaments within actin:myosin filament bundles 
(Maekawa et al., 1999). p160ROCK interacts with and phosphorylates the myosin 
binding subunit of myosin light chain phosphatase and thereby inactivates it (Kawano 
et al., 1999). This leads to increased levels of myosin phosphorylation, which then can 
cross-link actin filaments and generate contractile force. At the rear of a migrating cell, 
this promotes movement of the cell body and facilitates detachment of the cell rear. 
Clearly, Rho activity at the front of a migrating cell is incompatible with membrane 
24 
 
protrusion and hence its activity must be inhibited at the leading edge. One such 
mechanism is through Rac. Expression of activated Rac has been shown to inhibit 
Rho function in many cell types, ranging from fibroblasts to neurons (Sander et al., 
1999).   
 
The activity of Rho-family GTPases is highly regulated in space and in time. Most of 
what is summarized above has been derived from techniques that do not resolve these 
dimensions. Recently, new imaging technologies allowing spatio-temporal resolution 
has led to insights that significantly extend the classic model (Pertz, 2010). First, Rho 
GTPase signaling dynamics occur on micrometer length scales and subminute 
timescales. Second, multiple subcellular pools of one given Rho GTPase can operate 
simultaneously in time and space to regulate a wide variety of morphogenetic events 
Third, complex spatio-temporal signaling programs that involve precise crosstalk 
between multiple Rho GTPase signaling modules regulate specific morphogenetic 
events (Pertz, 2010). 
 
1.5 hepaCAM 
1.5.1 Identification of hepaCAM  
The identification of hepaCAM was derived from the sequence analysis of another 
gene, HEPN1. Previously, gene HEPN1 was identified by suppression subtractive 
hybridization (Moh et al., 2003) in a study aiming to identify altered gene expression 
in human hepatocellular carcinoma (HCC). HEPN1 was significantly suppressed in 
HCC samples, HCC cell lines and cell lines derived from diverse human cancers. 
Gene HEPN1 maps to chromosome 11q24.2; the protein product consists of 88 amino 
25 
 
acids with a molecular weight of about 10 kD. The distribution of HEPN1 protein is 
predominantly intracellular. Functionally, HEPN1 suppresses cell growth and induces 
apoptosis (Moh et al., 2003).  
 
A BLAST search with the HEPN1 sequence revealed an uncharacterized mRNA 
sequence of 2465 bp in the database (GenBank AL834419). Interestingly, this 
sequence contained the entire antisense strand of HEPN1 in its 3’-noncoding region 
and is deficient in the 5’-noncodign region. Using the gene specific primer at the 5’-
end of HEPN1 antisense strand and the adaptor primer, a new gene was identified 
from a human normal liver cDNA library. This new gene was later designated 
hepaCAM  (Moh e t al., 2005a).   
 
1.5.2 Sequence and structural characteristics of hepaCAM 
Gene hepaCAM is mapped to the minus strand of the human chromosome 11q24.2 
and contains 7 exons ranging in sizes from 71 to 2252 bp (Moh et al., 2005a). The 
start codon is located in exon 1 and the stop codon is positioned in exon 7. Intron  
sizes vary greatly from the longest intron 1 (10,851 bp) to the shortest intron 5 (285 
bp). 
  
The full-length cDNA of hepaCAM is 3244 bp long. It contains a 5’ UTR of 44 bp, a 
deduced coding region of 1251 bp with ATG as start codon and TGA as stop codon, 
and a 3’ UTR of 1949 bp. An in-frame termination codon TAG is present at 24 
nucleotides upstream of the putative initiating methionine, indicating the completion 






























Figure 1-2 Identification of hepaCAM based on the sequence analysis of 
HEPN1. An uncharacterized mRNA sequence of 2465 bp
 
(AL834419) was 
identified using a BLAST search with HEPN1. This sequence (a partial ORF) 
contains the entire antisense strand of HEPN1 in its 3’-noncoding region and is 
deficient in the 5’-noncoding region. Based on this sequence, a new gene was 
isolated from a human normal liver cDNA
 
library and designated hepaCAM. 
Gene hepaCAM is mapped to human chromosome 11q24 and  its genomic DNA 
sequence contains  7 exons. 
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 polyadenylation sequence (AATAAA), which signals for poly-A addition, are 
identified in the sequence. hepaCAM sequence does not show significant similarity 
with any known genes.  
 
The protein product of hepaCAM is a type I integral transmembrane immunoglobulin 
(Ig)-like cell adhesion molecule of 416 amino acids (Moh et al., 2005a). hepaCAM 
protein contains an extracellular domain comprising a signal peptide (residues 1-33) 
and two Ig-like loops (residues 40-142; 159-224), a transmembrane segment (residues 
241-263), and a cytoplasmic tail (residues 264-416). hepaCAM displays structural 
similarities to Ig-like CAMs like JAM1, CAR and ESAM (Moh et al., 2005a). 
Typically, they contain an extracellular domain with two Ig-like domains (V and C2 
domains), a transmembrane segment, and a cytoplasmic tail. Two cysteine residues 
flanking the C2 Ig domain of hepaCAM contribute to the formation of intrachain 
disulfide-linked loop (Fig. 1-3). 
 
1.5.3 Expression of hepaCAM 
Gene hepaCAM is widely expressed in normal human tissues including liver, brain, 
breast, muscle, lung, retina, uterus, etc. (Moh et al., 2008) but significantly 
downregulated in HCC tissues and suppressed in tissue samples of human tumors of 
kidney, breast, prostate, uterus, ovary, colon, lung, stomach and rectum (Moh et al., 




1.5.4 Subcellular localization of hepaCAM 
The subcellular localization of hepaCAM is cell density-dependent (Moh et al., 2005a, 
b). When the cells are well-spread, hepaCAM protein is localized to punctuate 
structures in the perinuclear area, cytoplasm, and at the tip of cell surface protrusions 
that are about to make contact with adjacent cell surfaces, forming zipper-like 
structures. When the cells are confluent, the hepaCAM is localized to a lesser extent 
in the perinuclear membrane and cytoplasm, and predominantly on the plasma 
membrane, particularly at cell-cell boundaries.  
 
1.5.5 Posttranslational modification of hepaCAM 
Six N-linked glycosylation sites have been predicted on the extracellular domain of 
hepaCAM. When expressed in MCF7 cells, the molecular weight of hepaCAM was 
reduced for ~25 kD after treating with PNGase F, which cleaves N-linked glycans 
(Moh et al., 2005b). Gaudry et al. (2008) demonstrated that the extracellular domain 
of hepaCAM is heavily glycosylated in both HEK and CHO cells, with approximately 
50% of the molecular mass attributed to glycans. There are significant differences in 
the glycosylation pattern between hepaCAM expressed in HEK and CHO cells 
(Gaudry et al., 2008). Since glycosylation can influence the behavior of protein, 
hepaCAM expressed in different cell lines may possess different properties.  
 
Multiple potential Ser/Thr/Tyr phosphorylation sites are present on the cytoplasmic 
domain of hepaCAM. A polyclonal antiserum generated by immunizing rabbits with a 
recombinant cytoplasmic domain of hepaCAM failed to detect the native form of 
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hepaCAM. However, dephosphorylated form of the protein was detected, indicating 
that hepaCAM is phosphorylated on the cytoplasmic domain (Moh et al., 2005b).  
 
1.5.6 Dimerization of hepaCAM 
Cross-linking studies showed that hepaCAM is able to form homodimer on cell 
surface through cis-interaction (Moh et al., 2005b). The dimerization is independent 
of the cytoplasmic domain as a mutant lacking the cytoplasmic segment also forms 
dimers.   
 
1.5.7 Functional characteristics of hepaCAM 
1.5.7.1 Cell growth control by hepaCAM 
hepaCAM exhibits inhibitory effect on cell growth. Such effect has been 
demonstrated by colony formation and cell proliferation assay (Moh et al., 2005a, b, 
2008). A study on cell cycle profile showed that hepaCAM arrests cell cycle at the 
G2/M phase (Moh et al., 2008). Interestingly, hepaCAM induces cellular senescence 
as defined by the enlarged cell morphology and increased β-galactosidase activity 
(Moh et al., 2008). The underlying mechanism is unclear but clues can be obtained 
from the experimental data that hepaCAM elevates the expression levels of p53, p21 
and p27, which are senescence-associated. Furthermore, knock-down of p53 results in 
reduction of p21 and alleviates senescence, suggesting that hepaCAM-induced 
cellular senescence is through the p53/p21 pathway (Moh et al., 2008). The 
suppressive effect of hepaCAM on cell growth together with the frequent loss of 




1.5.7.2 The effects of hepaCAM on cell-ECM interaction 
Besides cell growth control, as a cell adhesion molecule, hepaCAM plays important 
roles in cell adhesion. Although hepaCAM does not clearly affect cell-cell adhesion 
(Moh et al., 2005b), it is capable of modulating cell-ECM adhesion. Cell spreading is 
significantly accelerated in hepaCAM-expressing HepG2 and MCF7 cells (Moh et al., 
2005a, b), while cell detachment is delayed (Moh et al., 2005b). Boyden chamber and 
wound healing assays revealed that hepaCAM increased motility of HepG2 cells 
(Moh et al., 2005a). Similar studies were performed on MCF7 cells. Due to the poor 
invasive nature of MCF7 cells, barely any cell migrated through the transwell 
membrane. However wound healing assay showed significant increase of cell motility 
by hepaCAM (Moh et al., 2005b). 
 
1.5.7.3 Interaction between hepaCAM and actin 
hepaCAM has been shown to be partially insoluble in Triton X-100 (Moh et al., 
2009b), indicating an association with the cytoskeleton. Immunofluorescence revealed 
the co-localization of hepaCAM and actin at cell boundaries, and co-
immunoprecipitation confirmed a direct interaction between hepaCAM and actin 
(Moh et al., 2008). Intriguingly, an intact hepaCAM is needed to establish a stable 
interaction with F-actin. Deletion of any of its domains (1st Ig, 2nd Ig, and cytoplasmic) 
would result in complete loss of the interaction. In addition, an intact hepaCAM is 
also required to modulate cell-ECM adhesion and cell motility as deletion of the 1stIg, 







1.5.7.4 Interaction between hepaCAM and caveolin-1 
Besides F-actin, hepaCAM has been reported to be associated with caveolin-1, an 
essential structural component of caveolae, through the 1st Ig domain (Moh et al., 
2009a). Since lipid rafts and its derivative caveolae serve as platforms for the 
assembly of protein complexes involved in cell signaling, the localization of 
hepaCAM in caveolae suggests a role of hepaCAM in signaling. Interestingly, 
caveolin-1 has a regulatory role on hepaCAM that re-expression of caveolin-1 
promotes the expression and caveolar-recruitment of hepaCAM. Although the 
fuctional significance of this interaction remains to be determined, it suggests that 
caveolin-1 may play a role in the cross-talk of hepaCAM with cell signaling processes 
(Moh et al., 2009a).  
 
1.5.8 hepaCAM in the central nervous system 
One of our recent studies showed that hepaCAM is able to induce differentiation of 
the human glioblastoma U373-MG cells (Lee et al., 2009). hepaCAM significantly 
increases the expression of the astrocyte differentiation marker glial fibrillary acid 
protein and induces morphological changes characteristic of glioblastoma cell 
differentiation (i.e. small cell bodies with long, thin processes). Similar to the effects 
on HepG2 and MCF7 cells, hepaCAM inhibits cell proliferation and accelerates cell-
ECM adhesion of U373-MG. However, cell motility is decreased by hepaCAM as 
demonstrated by wound closure assay and Boyden chamber assay (Lee et al., 2009), 
suggesting that hepaCAM has different functional roles in different cell types, 
probably due to distinct post-translational modification and/or protein-protein 
interactions. 
CHPATER 2  HYPOTHESES AND OBJECTIVES 
 
The novel immunoglobulin-lilke cell adhesion molecule hepaCAM has been recently 
discovered and characterized. It is widely expressed in normal human tissues and 
often down-regulated in a variety of tumors. Restoration of hepaCAM in cancer cell 
lines leads to inhibition of cell growth and promotion of cell-ECM interaction. The 
frequent loss of hepaCAM in human cancers and the inhibitory effect of hepaCAM on 
cell growth suggest its role as a putative tumor suppressor.  
 
The present study aims to further investigate the characteristics of hepaCAM. Two 
main subjects will be embraced: firstly, the molecular basis that underlies the 
hepaCAM-mediated cell-ECM, with an emphasis on the integrin-mediated signaling; 
and secondly, the proteolytic processing of hepaCAM.   
The hypotheses are: 
1. hepaCAM mediates cell-ECM interaction through affecting the integrin-
mediated signaling 
2. hepaCAM undergoes a proteolytic cleavage that is functionally important 
The principal objectives of this study include: 
1. To explore the interaction between hepaCAM and integrins; 
2. To elucidate the effects of hepaCAM on the down-stream signaling events of 
integrins as well as cellular behaviors;  
3. To delineate the enzymatic mechanisms that underlie hepaCAM cleavage; 
4. To investigate the functional significance of hepaCAM cleavage.
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 CHAPTER 3  MATERIALS AND METHODS 
 
3.1 Cell cultures 
3.1.1 Cell line and culture condition   
The human breast carcinoma MCF7 cells were purchased from the American Type 
Culture Collection (Manassas, VA) and maintained in an incubator at 37°C with 5% 
CO2 humidified atmosphere in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, 
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Life 
Technologies, Gaithersburg, MD). 
 
3.1.2 Passaging cells 
Cells were subcultured when they reached 80-100% confluence. The culture medium 
was removed and the cells were washed once with 1× phosphate buffered saline 
(PBS). To cells in T75 flasks, 2 ml of 1× trypsin/ethylenediaminetetraacetic acid 
(EDTA) (Gibco BRL) was added and incubated at 37C for 2-5 min or until the cells 
were detached. Approximately 5 ml of culture medium was added to the flask and the 
cells in clumps were dispersed by repeated pipetting. Five ml of cells were removed 
and fresh medium was added to the remaining cells in the flask to a final volume of 
10 ml. If cells were to be counted, 50 µl of the cell suspension was mixed with 50 µl 
of 0.8 mM trypan blue in PBS on a piece of parafilm. The mixture was then applied to 
a haemocytometer and at least 100 cells were counted. The number of cells/ml was 
calculated using the following formula: 
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 Number of cells/ml = the average count/square of haemocytometer × the dilution 
factor × 104  
 
3.1.3 Storing cells 
Trypsinized cells were pelleted at 1,000 rpm for 5 min. The supernatant was discarded 
and the cells were resuspended in fresh freezing medium made up of 8% dimethyl 
sulfoxide (DMSO) in culture medium containing 10% FBS. The concentration of cells 
should be about 2 × 106 cells/ml of freezing medium. One ml-aliquot of the 
suspension was dispensed into each cryotube and stored at -80°C for overnight before 
transferring to liquid nitrogen for long-term storage. 
 
3.2 Determination of nucleic acid concentration 
The concentration and purity of DNA and RNA were determined by measuring their 
optical density (OD) at 260 and 280 nm. The concentration of DNA or RNA in a 
diluted solution was calculated using the molar extinction coefficient (OD260 = 1 = 50 




× dilution factor × 50 µg/µl = Concentration of DNA µg/µl  
OD
260 
× dilution factor × 40 µg/µl = Concentration of RNA µg/µl  
 
The ratio OD260/OD280 was determined to estimate the purity of nucleic acids. Pure 
DNA or RNA has a ratio of 1.8-2.0. A ratio less than 1.8 indicates that there may be 
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proteins and/or other UV (ultraviolet) absorbers the sample. A ratio higher than 2.0 
indicates that the samples may be contaminated with chloroform or phenol. 
 
3.3 Isolation of total RNA from cells 
Total RNA was prepared from cultured cells using the RNeasy Kit (Qiagen, Hilden, 
Germany), and when necessary, contaminating DNA was digested on-column using 
the RNase-Free DNase Set (Qiagen). Cells were resuspended in 600 µl of -
mercaptoethanol-containing RLT buffer and homogenized by repeated pipetting or by 
passing through a 20-guage needle fitted to syringe. One volume of 70% ethanol was 
then added to the lysate and mixed. The mixture was applied to an RNeasy spin 
column with a 2-ml collection tube and centrifuged. The flow-through was discarded 
and 350 µl of buffer RW1 was pipetted into the spin column. After centrifugation, the 
spin column was transferred to a new 2-ml collection tube and washed twice with 500 
µl of buffer RPE. The RNA was then eluted into a fresh collection tube from the spin 
column by adding 30 µl of RNase free water and centrifuging at 10,000 rpm for 1 min. 
Unless otherwise stated, all centrifugations were carried out at 10,000 rpm for 15 sec.  
 
Digestion of DNA could be carried out during RNA extraction. After immobilization 
of RNA on the spin column and washing with buffer RW1, DNase I mix containing 
10 µl (30 units) of DNase I stock solution and 70 µl of buffer RDD was added 
directly onto the spin column membrane and incubated at room temperature for 20 
min. The reaction was terminated by the addition of 350 µl of buffer RW1 for 5 min. 
After centrifugation, the column was washed with buffer RPE as described above. 
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To ensure the integrity of RNA, samples of the purified RNA were separated by gel 
electrophoresis using standard 1% agarose gels containing ethidium bromide as 
described in Section 3.7. The 28S and 18S ribosomal RNAs should appear as distinct 
bands on the stained gel. In addition, the intensity of the 28S ribosomal RNA band 
should be approximately twice the amount of the 18S RNA. 
 
3.4 Semi-quantitative RT-PCR 
RT-PCR was performed to examine the mRNA expression of specific genes or to 
isolate the sequence of a gene for molecular cloning. RT-PCR was performed using 
the OneStep RT-PCR kit (Qiagen). 
TABLE 3-1 Primers for RT-PCR 


















5’ ttctagatcattttccctcatacttcgg 3’ 
Housekeeping gene: 
GAPDH: 









TABLE 3-2  Semi-quantitative RT-PCR components 
Component Volume (µl) 
H2O 11 
5× One-step RT-PCR buffer  5 
dNTP Mix (10 mM)  1 
Primer 1 (10 µM)   1.5 
Primer 2 (10 µM)  1.5 
DNase-treated RNA (50 ng/µl)                           4 
One-step RT-PCR Enzyme Mix    1 
  
Final volume 25 
Q solution was added into the reaction for amplifying template with high GC content. 
 
TABLE 3-3 Semi-quantitative RT-PCR conditions 
Reaction Temperature Time Cycles 
RT 50 or 55C 
(55C for GC-rich 
template) 
 
30 min 1 
 
Inactivation of RT 
 




















3.5 Preparation of CaCl2 competent E. coli cells 
E. coli strain JM109 frozen stock was streaked onto a Luria broth (LB) agar plate and 
incubated overnight at 37°C. Following the protocol obtained from the Current 
Protocols in Molecular Biology, a single bacterial colony was inoculated into 50 ml of 
LB medium and cultured overnight at 37C with shaking at 250 rpm. Two ml of 
bacterial culture was added into 200 ml of pre-warmed LB medium and grown to an 
OD590 of 0.375. The bacteria were aliquoted into four 50-ml pre-chilled, sterile 
polypropylene tubes and incubated on ice for 10 min. The cells were harvested by 
centrifugation without brake at 3,000 rpm for 7 min at 4C. Each pellet was gently 
resuspended on ice in 10 ml of ice-cold CaCl2 solution followed by centrifugation at 
2,500 rpm for 5 min at 4C. A second resuspension in 10 ml of ice-cold CaCl2 
solution was carried out. The cells were incubated for 30 min on ice before 
centrifugation. Finally, each pellet was resuspended in 2 ml of ice-cold CaCl2 solution 
and dispensed in 100 µl-aliquots into pre-chilled sterile 1.5-ml microcentrifuge tubes 
before storing at -80C. 
 
3.6 Restriction endonuclease digestion of DNA 
Most restriction digestions were generally carried out in a final volume of 20 µl or  
50 µl containing the DNA, restriction enzymes, bovine serum albumin (BSA) and 
applicable buffer as supplied by Promega. The reactions were incubated for a 
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minimum of 1 h at 37C. Double digests were carried out simultaneously unless the 
buffer conditions were not suitable for both enzymes. In the latter cases, one digest 
was performed, purified with the QIAquick PCR Purification kit (Qiagen), and 
followed by the second enzyme digest. 
 
3.7 Agarose gel electrophoresis 
DNA or RNA was usually separated on a 1% agarose gel. To prepare a 1% SeaKem 
LE agarose (BioWhittaker, Walkersville, MD) gel, 0.5 g of agarose was added to  
50 ml of 1× TAE buffer and microwaved until the agarose was completely dissolved. 
The agarose mixture was cooled under running tap water to about 45C before adding 
2.5 µl of 10 mg/ml ethidium bromide (Biorad, Richmond, CA). The mixture was then 
poured into a cast with a well comb and allowed to solidify. Once set, the comb was 
removed and the gel was submerged in 1× TAE buffer in the electrophoresis tank. 
Samples were mixed with gel loading buffer prior to application to the wells. The gel 
was then electrophoresed at 120 V for approximately 45 min. The nucleic acid was 
visualized under UV light. 
 
3.8 Purification of DNA from agarose gel 
The desired DNA fragment was quickly excised under UV light and the DNA was 
recovered by centrifuging the gel slice over siliconized glasswool in a 0.6-ml 
microcentrifuge tube placed in a 1.5-ml microcentrifuge tube. The DNA eluant was 
purified using either the QIAquick PCR Purification kit (Qiagen). Briefly, 5 volumes 
of buffer PB were added to 1 volume of the eluant. The mixture was transferred into a 
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QIAquick spin column and centrifuged. The column was washed with 750 µl of 
buffer PE. Subsequently, DNA was eluted with 10-50 µl of H2O. All centrifugation 
steps were carried out at 13,000 rpm for 1 min at room temperature. 
 
3.9 DNA ligation 
In a ligation reaction, T4 DNA ligase (Promega) covalently links the phosphodiester 
bonds between the insert DNA and the vector DNA to join the two fragments together. 
Ligation was performed in a total volume of 10 µl containing appropriate molar ratios 
of vector and insert DNA (usually 1:2), 1 µl T4 DNA ligase and 1× ligase buffer, and 
incubated either for 1-2 h at room temperature or overnight at 4C. 
 
3.10 Transformation of E. coli 
Transformation facilitates the uptake and expression of DNA by a living cell. Ten µl 
of ligation mix was added to 100 µl of JM109 competent cells, mixed, and left on ice 
for 30 min. The cells were then heat-shocked at 42C for 45 sec before rapidly 
returning the tube to ice for 2 min. After addition of 900 µl of LB medium, the 
bacteria were incubated with shaking at 150 rpm for 90 min at 37C. The cells were 
then pelleted by centrifugation at 2,000 rpm for 3 min. Excess supernatant was 
discarded, leaving approximately 200 µl in the tube. The cells were then resuspended 
and plated onto LB agar plates containing the appropriate antibiotic. For blue/white 
selection, the LB agar plates were spread with 20 µl of X-Gal and 100 µl of IPTG 






3.11 Plasmid miniprep 
A bacterial colony or an aliquot of bacterial glycerol stock was inoculated into 3 ml of 
LB medium supplemented with the appropriate antibiotic. The inoculated bacteria 
were cultured at 37C overnight with shaking at 250 rpm. Two ml of bacteria were 
pelleted by centrifugation at 13,000 rpm for 1 min. Plasmid extraction was carried out 
using the QIAprep® Miniprep kit from Qiagen according to the manufacturer’s 
instruction. The pellet was resuspended in 250 µl of buffer P1 before lysing in 250 µl 
of buffer P2. The mixture was gently inverted 4-6 times till a clear and viscous lysate 
was obtained. Unwanted materials including bacterial cell wall fragments, proteins, 
and chromosomal DNA were precipitated by the addition of 350 µl of buffer N3 and 
centrifugation at 13,000 rpm for 10 min. The clear supernatant containing plasmid 
DNA was transferred to a spin column and centrifuged at 13,000 rpm for 1 min. The 
column was washed with 500 µl of buffer PB and 750 µl of buffer PE. Plasmid DNA 
was then eluted with 50 µl of sterile H2O and stored at -20C.  
 
3.12 Bacterial glycerol stock 
Glycerol was diluted to 50% in H2O and filter-sterilized. Three hundred and fifty µl 
of bacterial culture was mixed with 150 µl of 50% glycerol and stored at  
-80C. 
 
3.13 Automated DNA sequencing   
DNA Sequencing reactions were performed with the ABI PRISM Big Dye Reaction 
Terminator Cycle Sequencing Kit version 3.1 (Applied Biosystems, Foster City, CA) 




Table 3-4 Primers for sequencing 








Table 3-5 Sequencing components 
Component Volume (µl) 
Double-stranded plasmid 
Big Dye terminator mix 
5× Sequencing buffer 






Final volume Add H2O to a final volume of 20 
µl 
 















The sequencing product was precipitated with 2 µl of 125 mM EDTA, 2 µl of 3 M 
sodium acetate and 50 µl of absolute ethanol for 15 min at room temperature before 
centrifugation at 13,000 rpm for 15 min at 4C. The pellet was washed in 250 µl of 
70% ethanol and centrifuged at 13,000 rpm for 5 min at 4C. The final pellet was air 
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dried before being reconstituted in sequencing loading buffer and analyzed on an ABI 
PRISM™ TM 337 automated sequencer (Applied Biosystems). 
 
3.14 Transient and stable transfection 
Cells used for transfection were seeded one day before transfection at a density such 
that they would be 40-70% confluent on the day of transfection. Transfections were 
carried out with the reagent of Lipofectamine Plus (Invitrogen) according to the 
manufacturer’s instructions. Cells were transfected in serum-free DMEM with DNA 
precomplexed with PLUS and Lipofectamine reagents for 3-5 h, after which, the 
medium containing the complexes was removed and replaced with DMEM medium 
supplemented with 10% FBS. 
 
For stable transfections, cells transfected in 35-mm plates were reseeded into 100-mm 
plates or T75 flasks after 24 h of transfection and selected under 800 µg/ml of G418 
(Sigma) or 10 µg/ml of blasticidin (Invitrogen) for 2 weeks. Thereafter, the cells were 
trypsinized and each cell picked under microscope was transferred into a well of a 24-
well plate containing parental cells at 20% confluence. Parental cells were added to 
stimulate the growth of the stable cell. The cells were then allowed to propagate in 
culture medium without antibiotics for 2 days before replacing with selection medium. 
The cells were kept in selection medium until all the parental cells were killed and the 
stable clone reached confluence. Alternatively, after trypsinizing the stable cells, the 
cells were seeded at very low density to allow it to grow into a small colony of about 
40 cells. Under microscope, the colony was gently detached and aspirated using a 
pipette tip and transferred to a 24-well plate. The cells were maintained until 
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confluent in selection medium. Once the cells were confluent, a fraction of them was 
used for Western blot analysis and immunocytochemistry to confirm the expression of 
the desired protein and cell homogeneity, respectively. The positive clones were 
subsequently expanded.  
 
For transient transfections, the transfected cells were cultured without antibiotic 
selection for 24-48 hours before assaying. 
 
3.15 Immunocytochemistry 
3.15.1 Indirect immunofluorescence 
Cells grown on coverslips were washed twice with PBS and fixed with 3.7% 
paraformaldehyde for 15 min at 37C. The subsequent steps were all carried out at 
room temperature. Following three 5-min washes with PBS, the cells were 
permeabilized with 0.2% Triton X-100 in PBS for 5 min. A second set of washing 
was carried out and the nonspecific sites on coverslips were blocked in 1% BSA in 
PBS. The cells were then incubated for 1 h with primary antibody diluted in 1% BSA, 
washed, and incubated for 1 h with Alexafluor-conjugated secondary antibody 
(Molecular Probes, Eugene, OR) diluted in 1% BSA. Excess secondary antibody was 
removed by washing 3 times in PBS. After a final rinse in H2O, the coverslips were 
mounted onto the microscopic slides with FluorSave reagent (Calbiochem, La Jolla, 
CA), and analyzed by fluorescence microscopy (Carl Zeiss, Germany) or confocal 





 3.15.2 Labeling of F-actin 
F-actin is efficiently labeled with fluorescent phalloidin conjugates. Phalloidin is a 
fungal toxin produced by the poisonous mushroom Amanita phalloides that acts by 
binding to and stabilizing F-actin. Stock solution of tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated phalloidin (Sigma) was prepared in DMSO at 1 
mg/ml. F-actin of fixed and permeabilized cells was labeled with 1 µg/ml of TRITC-
conjugated phalloidin diluted in PBS for 1 h at room temperature. 
 
3.16 MTT assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay measures 
cell viability. The assay is based on the reduction of the yellow MTT into purple 
formazan crystals catalyzed by enzymes produced only in metabolically active live 
cells. 
 
To evaluate cell viability, a volume of 100 µl of MTT (Roche; 5 mg/ml in PBS) was 
added to cells transfected for 48 h in a 6-well culture plate. After 3 h of incubation at 
37C, cells were lysed and formazan crystals were dissolved in 1 ml of isopropanol 
with 0.4 N HCl. Wells containing all admixtures except cells were used as blanks. OD 
was read at 570 nm using an ELISA reader. Cell viability (CV) was computed by the 
following equation: 
 





where ODe = OD reading of experiment; ODc = OD reading of control. Cell viability 
of control was regarded as 100%. 
 
To assess the rate of cell proliferation, 2 × 104 cells were seeded and cultured in six 6-
well plates in triplicates. MTT assay was carried out once the cells had attached to 
establish the base line of cell growth. At every 24 h of cell culture for 5 days, MTT 
assay was performed to evaluate the cell viability. The growth rate of each cell line 
was presented as fold of increase in cell viability against the respective base line 
obtained on the day of seeding cells. 
 
3.17 Colony formation  
This assay was performed to evaluate the effect of the gene of interest on cell growth 
in colony form. Transfected cells were cultured in selection medium containing  
10 µg/ml of blasticidin or 800 µg/ml of G418 for 2 weeks without trypsinization 
while medium was refreshed every 2 days or 3-4 days, respectively. The cell colonies 
formed at the end of experiment were visible and the number of colonies was counted. 
  
3.18  Cell cycle analysis 
Cells were fixed in 70% ethanol and stored overnight at -20°C. Immediately before 
analysis, the cells were re-suspended in staining solution (200 µg/ml propidium iodide, 
0.1% Triton X-100 and 2 mg/ml RNase A) and incubated for 30 min at room 
temperature. Cell cycle distribution was determined using a Beckman Coulter Epics 
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Altra flow cytometer (Germany). Data were analyzed using the WinMDI (Joseph 
Trotter) software version 2.8. 
 
3.19 Cell adhesion assay 
For cell attachment assay, plates were coated with fibronectin (10 µg/ml; Santa Cruz) 
and allowed to polymerize for 1 h at 37C or at room temperature. The plates were 
then blocked by 1% BSA for 1 h. Cells were seeded and allowed to adhere. After 5 
min, unattached cells were washed away by 1× PBS. Attached cells were stained by 
1% crystal violet. After air-dried, the stained cells were desolved in 1% SDS and 
optical absorbance of the solution at wavelength 490 nm was measured.   
 
To examine cell spreading, cells were seeded onto the coated coverslips and incubated 
under standard culture conditions. Cell morphology was observed by microscopy. 
Unspread cells were defined as round cells while spread cells were defined as cells 
with extended processes. The percentage of cells demonstrating spread morphology 
was quantified in 10 randomly selected fields. 
 
3.20 Wound healing assay 
Cell migration was assessed by the wound healing experiment on monolayer cells. 
Cells were seeded in 35-mm culture plates at high density and allowed to form 
confluent monolayers overnight. Wounds were made by sterile plastic 200-µl 
micropipette tips and allowed to be healed in culture medium containing 10% FBS. 
Microscopic pictures representing the changes in diameter (D) of each wound were 
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taken at 24 and 48 hours. By measuring the remaining gap space on the pictures, the 
percentage of wound closure was computed into ratio (D24/48h/Dinitial × 100%).  
 
3.21 Chemical crosslinking  
A monolayer or a single suspension of cells were incubated in PBS containing 2 mM 
dithiobis(succinimidylpropionate) (DSP; Pierce) dissolved in DMSO or 3,3'-Dithiobis 
(sulphosuccinimidyl propionate) (DTSSP; Pierce) dissolved in H2O at room 
temperature for 30 min. The reaction was quenched with the addition of 20 mM Tris-
HCl pH 7.5 for 15 min. Single-cell suspension was assured by microscopic 
observation before and after chemical crosslinking reaction. DTSSP-crosslinked 
proteins were resuspended in Laemmli sample buffer without reducing agent 50 mM 
dithiothreitol (DTT) unless indicated. Cell lysate was prepared in 
radioimmunoprecipitation assay (RIPA) buffer containing 10 mM iodoacetamide to 
inhibit formation of nonspecific disulfide linkages.  
 
3.22 Preparation of whole cell extracts  
Cells were scraped in RIPA buffer containing protease inhibitors followed by 
incubation on ice for 15 min. The cell lysate was cleared by centrifugation at  
13,000 rpm for 10 min at 4C. Protein samples were mixed with an equal volume of 2 





3.23 Subcellular fractionation 
Subcellular fractionation was performed using the Subcellular Protein Fractionation 
Kit (Thermo Scientific, Waltham, MA) according to the manufacturer’s instruction. 
Briefly, cells were harvested and the cell pellet was incubated with Cytoplasmic 
Extraction Buffer at 4°C for 10 min. After centrifugation at 500× g for 5 min, the 
supernatant containing the cytoplasmic proteins was stored and the remaining pellet 
was incubated with Membrane Extraction Buffer at 4°C for 10 min. The supernatant 
after centrifugation at 3,000× g for 5 min was the membrane extract. The remaining 
pellet was incubated with Nuclear Extraction buffer at 4°C for 30 min with vortex to 
extract soluble nuclear proteins after centrifugation at 5,000× g for 5 min. The 
chromatin-bound proteins were extracted by incubating the remaining pellet with 
Nuclear Extraction Buffer plus CaCl2 and Micrococcal Nuclease at room temperature 
for 15 min followed by vortex and centrifugation at 16,000× g for 5 min. The 
remaining pellet was incubated with Pellet Extraction Buffer containing protease 
inhibitors at room temperature for 10 min followed by vortex. After centrifugation at 
16,000× g for 5 min, the supernatant was the cytoskeletal extract.   
 
3.24 in vitro translation 
Pure proteins of hepaCAM and integrin β1 were obtained by in vitro translation using 
TNT® Quick Coupled Transcription/Translation Systems (Promega) and Human In 
Vitro Protein Expression Kit (Pierce, Rockford, IL), respectively, according to the 
instructions of the manufacturers. Briefly, when using the Promega kit, components 
listed in Table 3-7 were mixed gently to prepare a reaction. The reaction was 
incubated at 30°C for 60-90 min followed by Western blot analysis for protein 
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expression or immunoprecipitation. For the Pierce kit, components listed in Table 3-8 
were mixed gently to prepare a 20 µl transcription reaction. The reaction was 
incubated at 32°C for 60-75 min. For translation reaction, components in Table 3-9 
were assembled and incubated at 28-32°C for 90 min. The final product was subjected 
to analysis by Western blot or immnoprecipitation. 
 
Table 3-7 Components for TNT® Quick Coupled Transcription/Translation 
Systems (Promega) 
Component Volume (µl) 
TNT® Quick Master Mix 
Methionine, 1 mM 











Table 3-8 Components for transcription reaction (Human In Vitro Protein 
Expression Kit, Pierce) 
Component Volume (µl) 
Nuclease-free Water 
5× Transcription Buffer 
NTP Mix 
Plasmid DNA template (0.5 µg/µl) 












Table 3-9 Components for translation reaction (Human In Vitro Protein 
Expression Kit, Pierce) 
Component Volume (µl) 
Lysate for protein Expression 
Accessory Proteins 
Nuclease-free Water 
Salt Solution A 
Amino Acid minus Met 
Amino Acid minus Leu 
RNA se Inhibitor (optional) 
Energy Mix 















3.25 Determination of protein concentration by the Bradford method 
The Bradford assay is a dye-binding assay based on the differential color change of 
Coomassie blue G dye as it binds to protein. In this study, the concentrations of 
proteins were determined by Bradford assay (Biorad) at OD595. 
 
One part of the Dye Reagent Concentrate was diluted in 4 parts of H2O to constitute 
the working solution. Twenty µl of protein diluted in PBS was mixed with  
1 ml of working dye solution and the absorbance measured. A standard curve was 
plotted by measuring the absorbance of BSA at concentrations ranging from 0.1 

















Figure 3-1 Protein standard curve. 
 
3.26 Western blot analysis 
3.26.1 Separation of proteins by polyacrylamide gel electrophoresis 
Denatured protein samples were loaded onto 10% sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE) gel and resolved by running in 1× 
SDS-PAGE running buffer at 150 V for 70 min or until the desired distance was 
reached. 
 
3.26.2  Protein transfer 
After electrophoresis, proteins were transferred from the gel onto polyvinylidene 
fluoride (PVDF) membrane (Biorad) using BioRad’s Mini Trans-Blot Electrophoretic 
Transfer Cell. The gel, membrane, Whatman filter papers and fiber pads were 
equilibrated in Towbin buffer for 15 min before assembly as illustrated in Figure 3-2. 
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The proteins were transferred from the gel (negative electrode) to the membrane 
(positive electrode) at 100 V for 60 minutes in Towbin buffer containing 0.1% SDS. 
 
 
Figure 3-2 Assembly for protein transfer. (Source: instruction manual of 
Biorad’s Mini Trans-Blot Electrophoretic Transfer Cell) 
 
3.26.3 Western blotting 
The membrane was rinsed with 1× tris buffered saline (TBS) and blocked in blocking 
buffer (5% skim milk) for 1 h. Incubation with primary antibodies diluted in blocking 
buffer was carried out either at room temperature for 1 h or 4C overnight. The 
primary antibodies used included mouse anti-V5 from Invitrogen, mouse anti-integrin 
1 (clone P5D2, for immunoprecipitation) from Abcam (Cambridge, MA), rat anti-
active integrin 1(clone 9EG7) from BD Biosciences (Sprks, MD), mouse anti-
calpain 1 from Biomed Diagnostics (White Citiy, OR), mouse anti-E-cadherin from 
Zymed Laboratories (San Francisco, CA), rabbit anti-integrin 1(for Western blot 
analysis), rabbit anti-integrin V, rabbit anti-p-paxillin (Y118), rabbit anti-p-FAK 
(Y397), rabbit anti-talin from Millipore (Billerica, MA), mouse anti-integrin 1 
(clone JB1B, for immunofluorescence), goat anti-integrin 2, goat anti-integrin 3, 
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rabbit anti-paxillin, rabbit anti-FAK, mouse anti-p53 and mouse anti-GAPDH from 
Santa Cruz. Blots were then washed three times in TBS/Tween 20 (TBS/T), 5 min 
each, and then incubated for 1 h in the appropriate horseradish peroxidase-conjugated 
secondary antibody (Santa Cruz). After four 5-min washes, the enzymatic activity was 
detected with chemiluminescence luminol reagent (Santa Cruz) or enhanced 
chemiluminescence (Thermo Scientific) and autoradiography. The band intensities 
were quantified with a GS-800 densitometer and QuantityOne software (Biorad). 
 
3.26.4 Stripping of Western blot 
The Western blot to be re-probed was stripped in two 15-min washes of stripping 
buffer. The membrane was then rinsed with 1× TBS before re-blocking.    
 
3.27 Immunoprecipitation 
Immunoprecipitation was used to purify the desired protein and co-
immunoprecipitation was performed to detect protein-protein interactions. Cell lysate 
prepared in NP-40 buffer was precleared with Protein G-agarose beads (Santa Cruz) 
for 1 h at 4C with agitation. The supernatant was recovered by centrifugation at 
2,500 rpm for 1 min. The precleared lysate was then mixed with protein G-agarose 
beads and specific antibody, and incubated overnight at 4°C before washing four times 
with RIPA buffer or PBS when a reduced stringency was desired. The beads were 
resuspended in 2× Laemmli sample buffer, boiled for 10 min and the eluted proteins 




3.28 GTPase activity assay 
Rho, Rac1, and Cdc42 activities were analyzed using the Rho and Rac1/Cdc42 
activation assay kits (Cell Biolabs, San Diego, CA), respectively. Briefly, serum-
starved cells were seeded onto fibronectin-coated Petri dishes and incubated for 30 
min or 3 h at 37C. Cell lysate was prepared according to the manufacturer’s 
instructions. Equal amount of protein per sample was incubated for 1 h at 4 °C with 
GST-sepharose loaded with either 400 g of GST-Rhotekin-RBD or 20 g of GST-
PAK1-PBD. Bound proteins were separated by SDS-PAGE and analyzed by Western 
blot using the supplied monoclonal antibodies against Rho, Rac1 and Cdc42. 
 
3.29 Time-lapse microscopy  
Serum-starved cells were plated on fibronectin-coated 35-mm Petri dishes in DMEM 
and allowed to adhere and migrate. Cell migration was monitored using the time lapse 
imaging system BioStation IM-Q (Nikon, Japan) at 5-min intervals for 8 h. The 
positions of nuclei were tracked using NIS-Elements Ar (Nikon) to quantify cell 
motility and to calculate velocities and directionalities. Five cells were quantified in 
each view for 5 views for each cell type. Cell velocity was calculated as the total path 
length (l) divided by time duration (t); directionality was defined as the ratio of 
distance between start and end points (d) over the total path length (l). 
 
3.30 Statistical analysis 
All statistical analyses were performed with the software InStat 3.0 (GraphPad, San 





normalized 1. Unpaired t test was used to compare the means of two groups. 
Nonparametric analysis of variance (ANOVA) was performed to compare the 
differences among more than two means. P < 0.05 was considered significant. 
CHAPTER 4       RESULTS 
4.1 Connection between hepaCAM and the integrin-dependent signaling 
4.1.1 Protein expression of hepaCAM in non-tumorous and tumorous breast 
cell lines 
As introduced previously, hepaCAM is frequently down-regulated in cancer cells. To 
examine the regulation of hepaCAM in breast cancer cells, protein expression of 
hepaCAM in two normal breast cell lines MCF10-A and MCF12-A and one tumorous 
cell line MCF7 was examined by Western blot using anti-hepaCAM antibody. No 
expression of hepaCAM was detected in all cell lines including the normal ones (Fig 
4-1). Although MCF10-A and MCF12-A are non-tumorous, they have been 
immortalized and may have altered gene expression compared to normal breast 
tissues. Thus hepaCAM expression may have been lost in the two cell lines.  
 
4.1.2 Stable transfection of hepaCAM into MCF7 cells 
Human breast carcinoma MCF7 cells were stably transfected with either 
pcDNA6B/V5-His or vector containing the entire hepaCAM sequence. Protein 
expression of hepaCAM in the two cell lines was examined by Western blot. A 75 kD 
band was detected in hepaCAM transfected cells while no protein expression was 
observed in the vector transfected cells (Fig 4-2). hepaCAM-expressing MCF7 cells 




























breast cell lines. Protein expression of hepaCAM
 
in MCF7, 
MCF10-A and MCF12-A cells (left panel) was examined by Western blot 
using anti-hepaCAM
 
antibody. MCF7 cells were stably transfected
 
with 
pcDNA6/V5-His vector [hepaCAM(-)] or vector containing the hepaCAM
 
sequence [hepaCAM(+)] (right panel). The expression of hepaCAM
 
in stable 
clones of MCF7 cells was examined by Western blot. 
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4.1.3 hepaCAM alters the cell-ECM interaction of MCF7 cells on a fibronectin  
substrate 
4.1.3.1 hepaCAM accelerates initial cell attachment  
Initial cell attachment refers to the adherence between cells and the binding substrate 
immediately after cell-ECM contact. This process is usually completed within 
minutes. The effects of hepaCAM on initial cell attachment were examined. 
hepaCAM(-) and hepaCAM (+) cells were plated on Petri-dishes coated with the 
ECM protein fibronectin. After 5 min, unattached cells were washed away by PBS 
and the attached cells were stained by crystal violet. The attachment rates of cells 
were derived from the OD readings at wavelength 570 nm compared with a 100% 
attachment control. As shown in Figure 4-2, the expression of hepaCAM increased 
the initial cell attachment by approximately 3 fold as compared to the control cells. 
 
4.1.3.2 hepaCAM increases cell spreading  
After initial cell attachment is cell spreading which is characterized by membrane 
protrusions in morphology. To examine the effects of hepaCAM on cell spreading,  
hepaCAM(-) or hepaCAM(+) stable clones of MCF7 cells were plated onto a 
fibronectin-coated surface. After 30 min, most of the control cells remained rounded 
while a significantly higher percentage of hepaCAM-transfected cells displayed 
numerous protrusions, exhibiting spread morphology, consistent with our previous 
results (Moh et al., 2005a, b). The percentage of hepaCAM transfected cells 
displaying a spread morphology was almost double that of the control cells (Fig. 4-3
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Figure 4-2 hepaCAM promotes initial cell attachment. (A)
 
hepaCAM(-) and 
hepaCAM(+) MCF7 cells were serum-starved overnight and seeded onto Petri-
 
dishes coated with 10 μg/ml fibronectin. After 5 min, unattached cells were 
washed away with PBS and attached cells were stained with 1% crystal violet.  
Microscopic pictures were taken. Magnification, 320 ×. As a control, the cells 
were allowed to spread for 3 h and the cell density of the corresponding cell line 
was considered as 100%.
 
The attachment rates of cells were derived from 
comparing the OD readings at wavelength 570 nm against the 100% control. (B) 
Bar charts depict the attachment rates. Data represent means ±
 




Figure 4-3 hepaCAM increases cell spreading. (A)
 
hepaCAM(-) and 
hepaCAM(+) cells were allowed to adhere on fibronectin
 
for 30 min and 
microscopic pictures were taken. Magnification, 320 ×. The percentage of cells 
demonstrating spread morphology was quantified in 5 randomly selected fields. (B) 
Bar charts depict the percentages of spread cells. Data represent means ±
 






4.1.3.3 hepaCAM promotes cell migration 
Cell migration involves repeated adhesion at the cell front and detachment at the cell 
rear. Such cyclic processes drive the cells to move forward. To examine if hepaCAM 
also affects cell migration, motility of hepaCAM(-) and hepaCAM(+) cells on 
fibronectin was monitored for 8 h by time-lapse microscopy under standard cell 
culture condition. The snap shot photos showed the morphology of vector or 
hepaCAM-transfected cells at 0, 2, 4, and 8 h (Fig. 4-4). hepaCAM-transfected cells 
displayed more extensive protrusions and lamellipodia than vector transfected cells 
during migration. The paths of migration of 5 representative cells of each cell line 
were tracked over a period of 8 h. The migration tracks revealed that the control cells 
were not very motile and their migration was random with low persistence. In contrast, 
a noticeable percentage of hepaCAM-transfected cells displayed substantial migration, 
leaving behind apparently longer migration paths (Fig. 4-5). The average cell velocity 
was increased approximately 5-fold by hepaCAM. The directionality was also 
significantly increased, indicating a higher persistence of cell migration.  
 
4.1.4 Interation between hepaCAM and integrin β1 
4.1.4.1 Integrin β1 is the major molecule mediating cell-ECM adhesion of  MCF7    
cells  
Cell adhesion is strictly dependent on the interaction between the ECM substrate and 
the adhesion molecules expressed on the cell surface. For most cell types, integrins 
are the major receptors that mediate cell-ECM adhesion (Hynes, 2002). Integrin β1 is 
the most highly expressed integrin in MCF7 cells (Doerr and Jones, 1996) and also an 
essential component of the fibronectin receptor. Both vector- and hepaCAM-
transfected cells were treated with either non-specific mouse IgG or an integrin β1
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Figure 4-4  Time-lapse microscopy of migration of hepaCAM(-) and 
hepaCAM(+) cells. hepaCAM(-) and hepaCAM
 





migration of cells was monitored for 8 h at 5-min 















Figure 4-5 The migration tracks, velocity and directionality of hepaCAM(-) 
and hepaCAM(+) cells.  (A)
 
The migration paths of 5 cells/view for 5 views of 
each cell line were tracked over 8 h. (B) The cell velocity was calculated by 
dividing the total path length by the time of duration. Directionality was 
determined as the ratio of the linear distance from the end point to the origin (d) 
over the total path length (l). Data represent means ±
 




function blocking antibody (clone P5D2) and spread on fibronectin. After 1.5 h, both 
IgG treated vector- and hepaCAM-transfected cells were almost fully attached, and 
hepaCAM transfectants were much more spread than the control cells. However, 
when integrin β1 function was blocked, the attachment of both vector- and hepaCAM-
transfectants was almost abolished (Fig. 4-6), indicating that integrin β1 is indeed the 
major molecule mediating cell-ECM adhesion of MCF7 cells. It also suggested that 
hepaCAM alone is not able to mediate cell-ECM adhesion.   
 
4.1.4.2 hepaCAM and integrin β1 are physically associated 
It has been reported that integrins are able to interact with other adhesion molecules 
such as the Ig superfamily of CAMs that hepaCAM belongs to (Brummer et al., 2001). 
To examine if hepaCAM interacts with integrin β1, co-immunoprecipitation was 
performed. The results showed no interaction between hepaCAM and integrin β1 was 
detected (Fig. 4-7, left panel). To strengthen the possible protein-protein interaction 
and avoid loss of signal during the stringent washing steps, the cells were treated with 
DSP, a cross-linking agent, before co-immunoprecipitation. Finally, hepaCAM was 
successfully detected in the integrin β1 immunoprecipitate using this method (Fig. 4-7, 
right panel). The data indicated that hepaCAM and integrin β1 coexist in one complex 
but the association may be relatively weak. 
 
4.1.4.3 cis/trans interaction between hepaCAM and integrin β1  
We then tested whether the association was in cis or trans. Cis is the conformation 
when two molecules interact on the same cell, while trans refers to the interaction of 





β1 is the dominant integrin
 
in MCF7. (A) The cells were treated 






blocking antibody and spread on 
fibronectin
 
coated surfaces for 1.5 h.  Magnification, 320×. (B) The floating cells were 
washed away by PBS and the attached cells were stained with 1% crystal violet and OD 
measured at 570 nm.  Attachment of  IgG
 
treated cells was considered 100% for each cell 




blocking antibody was 
calculated accordingly. Data represent means ±
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 monolayer or disaggregated into single-cell suspension. The cells were then treated 
with DTSSP, a cross-linking agent that is impermeable to cell membranes, to cross-
link proteins on the cell surface before lysis. The results showed that hepaCAM was 
co-immunoprecipitated with integrin β1 from the cell lysate of cells in both 
monolayer and single-cell suspension (Fig. 4-8), indicating that hepaCAM and 
integrin β1 interact with each other on the same cell. Since this method was only able 
to confirm cis interaction, the possibility of trans interaction was not excluded.  
 
4.1.4.4 Direct/indirect interaction between hepaCAM and integrin β1 
Next, we studied whether the interaction was direct or indirect. Pure hepaCAM and 
integrin β1 proteins were obtained by in vitro translation. hepaCAM was translated 
using a rabbit reticulocyte translation system (Promega) while integrin β1 was 
translated from a human translation system (Pierce). The expression of the resulted  
proteins was examined by Western blot analysis (Fig. 4-9 A). While the translated 
integrin β1 was ~130 kD, almost identical to the endogenous integrin β1 expressed in 
MCF7 cells, the translated hepaCAM was ~50 kD, smaller than the transfected 
hepaCAM in MCF7 cells, probably due to different posttranslational modification. 
The obtained hepaCAM and integrin β1 proteins were mixed and incubated overnight 
at 4°C before immunoprecipitation. No association between in vitro translated 
hepaCAM and integrin β1 proteins was found (Fig. 4-9 B), suggesting that the 
interaction between hepaCAM and integrin β1 might be indirect. 
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Figure 4-8 cis-interaction between hepaCAM and integrin
 
β1. A monolayer or 




























proteins were obtained by in vitro translation system 
and the protein expression was examined by Western blot using anti-integrin
 
β1 and 





























4.1.5 Domain dependence of hepaCAM-integrin β1 interaction 
4.1.5.1 Generation of truncated mutants of hepaCAM 
Several truncated mutants were generated to study the dependence of hepaCAM-
integrin β1 interaction on different domains of hepaCAM. The amino acid sequences 
of the 1st Ig, the 2nd Ig, and the cytoplasmic domain of hepaCAM are denoted in 
Figure 4-10 A using distinct colors. The mutant hCAM∆1st Ig was generated by 
deleting residues 33-145, hCAM2nd Ig by deleting residues 155-227 and hCAMtail 
by deleting residues 33-227. The signal peptide was retained at the N-terminus of 
each mutant (Fig. 4-10 B). The sequences were cloned into the eukaryotic expression 
vector pcDNA6B/V5-His.  
 
4.1.5.2 Protein expression of hepaCAM mutants  
The protein expression of the truncated mutants of hepaCAM was examined by 
Western blot analysis (Fig. 4-11). Given the same amounts of total cell lysate, the 
expression level of hCAM∆1stIg was relatively low compared to wild-type (WT) 
hepaCAM and other mutants, while hCAM∆tail had a very high expression. 
Interestingly, both hCAM∆2ndIg and hCAM∆tail exhibited two distinct bands. 
Previously it has been shown that hepaCAM is glycosylated on its extracellular 
domain (Moh et al., 2005b). Perhaps the thicker bands at a higher molecular weight of 
hCAM∆2ndIg and hCAM∆tail represented differentially glycosylated protein products. 
These data suggested that deletion of any of the domains would affect the level of 






















Figure 4-10 Truncated mutants of hepaCAM. (A) Protein sequence of hepaCAM. 
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Figure 4-11 Protein expression of hepaCAM mutants. Plasmids containing 
wild type hepaCAM, hCAM∆1st
 



























possess the 1st Ig domain while hCAM∆1st Ig does not. Thus the first Ig domain 
probably contains the major site where varied glycosylation occurs.  
 
4.1.5.3 Subcellular localization of hepaCAM mutants 
Plasmids containing hepaCAM, hCAM∆1st Ig, hCAM∆2ndIg, or hCAM∆tail were 
stably transfected into MCF7 cells. The subcellular localization of the proteins was 
revealed by immunofluorescence by staining the cells with anti-V5 antibody (Fig. 4-
12). WT hepaCAM had a clear distribution on the plasma membrane, especially on 
the cell boundary, consistent with previous observations (Moh et al., 2005a, b). There 
was also some distribution in the cytoplasm, particularly in the perinuclear area. 
Interestingly, hCAM∆1st Ig exhibited localization distinct from WT hepaCAM. The 
distribution on plasma membrane was completely lost. Instead, the protein was 
extensively distributed in the cytoplasm, highly resembling the pattern of endoplasmic 
reticulum. In contrast, hCAM∆2ndIg retained the plasma membrane distribution, 
showing a pattern similar to WT hepaCAM. However, the intracellular distribution 
was more concentrated in the perinuclear area. The distribution of hCAM∆tail was 
almost identical to that of hCAM∆2ndIg except that the protein was distributed to 
some dot-like structures in the cytoplasm. These results suggested that the 1st Ig 
domain is important for localization of hepaCAM on the plasma membrane. Secondly, 
the 2ndIg and the cytoplasmic domain, although not critical for plasma membrane 
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of the proteins was revealed by immunofluorescence
 
with anti-V5 antibody 




4.1.5.4 Association between integrin β1 and hepaCAM mutants 
Next we determined if the physical association between hepaCAM and integrin β1 is 
dependent on certain domain(s). The cell lysate of MCF7 stable clones of WT 
hepaCAM, hCAM∆1st Ig, hCAM∆2ndIg and hCAM∆tail was immunoprecipitated 
with anti-integrin β1 antibody followed by immunoblotting using anti-V5 antibody. 
The results showed that all mutants were able to be co-immunoprecipitated with 
integrin β1 (Fig. 4-13), indicating that deletion of any of the 1st Ig, the 2nd Ig, or the 
cytoplasmic domain does not affect the physical association between hepaCAM and 
integrin β1.  
 
4.1.5.5 Association between hepaCAM and α subunits of integrin 
We also attempted to identify the integrin α subunit that interacts with hepaCAM. Co-
immunoprecipitation was performed using antibodies against the major types of α 
integrins expressed by MCF7 cells: integrin α2, α3, and αV. However, no interaction 
between hepaCAM and the α integrins tested could be detected (Fig. 4-14). 
 
4.1.6 hepaCAM alters the expression and activity of integrin β1 
4.1.6.1 hepaCAM up-regulates the protein expression of integrin β1 
Subsequently, we examined if the expression of integrin β1 was affected by 
hepaCAM. Vector- or hepaCAM-transfected cells were spread on fibronectin for 0.5, 
1.5 or 3 h followed by cell lysis and Western blot analysis. The results showed that 
the expression of total integrin β1 in hepaCAM-transfected cells was markedly 
increased at all time points when compared to the control cells (Fig. 4-15). RT-PCR 
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Figure 4-13 Association between integrin
 
β1 and hepaCAM mutants. Cell 
lysate
 








antibody followed by immunoblotting
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hepaCAM(-) or hepaCAM(+) cells were plated on fibronectin. At the indicated 
time points, the cells were lysed
 
and subjected to Western blot. An anti-integrin
 
β1 antibody was used to detect the total protein level of integrin
 
β1. GAPDH 
served as the loading control. (B) The bar chart shows the intensity of each protein 
band. Intensity of the band representing the vector transfectants
 
at 0.5 h was 




was carried out to determine if the expression of integrin β1 was altered at the mRNA 
level. As shown in Figure 4-16, the mRNA level of integrin β1 in hepaCAM-
transfected cells was comparable to that in the control cells at both 30 min and 3 h, 
suggesting that the hepaCAM-mediated integrin β1 up-regulation was not at 
transcription level. 
 
4.1.6.2 hepaCAM increases the active form of integrin β1 
To determine the activation of integrin β1, an antibody specific for the active form 
(high affinity state) of integrin β1 (9EG7) was used to perform immunoprecipitation. 
hepaCAM transfectants expressed a significantly higher level (approximately 1.5 fold) 
of active integrin β1 than the control cells at both 0.5 and 3 h time points (Fig.4-17). 
 
4.1.6.3 hepaCAM increases the clustering of integrin β1 
Activation of integrins is usually accompanied by lateral clustering (Li et al., 2003), 
which forms distinct patterns on the cell-ECM interface. To examine the effects of 
hepaCAM on integrin β1 clustering, the cells were spread on fibronectin-coated plate  
for 30 min followed by immunostaining with anti-V5 antibody. Consistent with the 
results in Figure 4-16, the immunofluorescence staining demonstrated robust clusters 
of integrin β1 in hepaCAM-transfected cells, whereas the integrin clusters observed in 
the control cells were considerably less (Fig. 4-18). 
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mRNA level of integrin
 
β1 in the cells was determined by semi-quantitative RT-
 
PCR. (B) The bar chart shows the intensity of each RNA band. Intensity of the 
band representing the vector transfectants
 
at 0.5 h was considered as 1. Data 










prepared from hepaCAM(-) or hepaCAM(+)  cells was immunoprecipitated
 
with 
an antibody specific for the active form of integrin
 
β1 (clone 9EG7) followed by 
Western blot. IgG
 
heavy chain bands served as a loading control. (B) The bar chart 
shows the intensity of each protein band. Intensity of the band representing the 
vector transfectants
 
at 0.5 h was considered as 1. Data represent means ±
 





Figure 4-18 hepaCAM increases the clustering of integrin
 
β1. The cells were 
spread on fibronectin
 
coated surface for 30 min and stained with anti-integrin
 
β1 
antibody. The staining was examined by confocal
 
microscopy. Bars, 10 μm. 
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4.1.6.4 Talin is not affected by hepaCAM  
Talin has been established as the key molecule in the regulation of integrin activation 
(Calderwood et al., 2004). Western blot analysis was carried out to determine the 
expression level of talin in control and hepaCAM-transfected cells. Our results 
showed that the level of talin was not altered in hepaCAM-transfected cells compared 
to the control cells (Fig. 4-19 A). Furthermore, co-immunoprecipitation revealed no 
physical association between hepaCAM and talin (Fig. 4-19 B), even in the presence 
of DSP. These data suggested that the hepaCAM-mediated activation of integrin β1 is 
not likely to be talin-dependent. 
 
4.1.7     hepaCAM affects focal contact assembly 
4.1.7.1     hepaCAM is not localized at sites of focal contacts 
Focal contacts are sites where integrin-mediated adhesions link to the actin 
cytoskeleton (Wozniak et al., 2004). These macromolecular assemblies serve to 
interconnect biochemical signaling between the ECM and the actin cytoskeleton. 
Therefore, it is important to investigate the influence of hepaCAM on focal contacts. 
To visualize if hepaCAM was localized at sites of focal contacts, hepaCAM-
transfected cells were spread on fibronectin for 30 min and double-stained for 
hepaCAM and paxillin. Paxillin is a functionally important component of focal 
contacts and is often used as a marker for focal contacts in image studies. The 
immunofluorescence showed no co-localization of hepaCAM and paxillin (Fig. 4-20), 






























were spread on fibronectin
 





(red). Bars, 10 μm. 
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4.1.7.2      hepaCAM regulates focal contact assembly in a temporal manner 
4.1.7.2.1 hepaCAM changes the phosphorylation of FAK and paxillin 
Next, we examined the effects of hepaCAM on the activity of two of the key 
components of focal contacts – focal adhesion kinase (FAK) and paxillin (Wozniak et 
al., 2004). These two proteins are activated through tyrosine phosphorylation (mainly 
Tyrosine 397 of FAK and Tyrosine 118 of paxillin) in response to integrin-ECM 
interactions. Western blot analysis showed that hepaCAM-transfected cells exhibited 
a higher total level of phospho-paxillin than the control cells at 30 min (Fig. 4-21). 
The level of phospho-FAK was not significantly changed. It is noteworthy that at 3 h, 
phospho-paxillin in hepaCAM transfectants appeared lower than the control cells, 
although the total level of paxillin remained higher than the control cells. There was 
also a decrease in phospho-FAK in hepaCAM-transfected cells compared to the 
control cells at 3 h. 
 
4.1.7.2.2 hepaCAM increases the formation of focal adhesions at early stage of 
cell-ECM contact 
The formation of focal contacts in vector- or hepaCAM-transfected cells was 
visualized by double-staining of paxillin and integrin β1. Focal contacts were more 
distinctly revealed by the co-localization of these two proteins. Immunofluorescence 
results showed that 30 min after plating on fibronectin, the control cells were not fully  
spread, and focal contacts were poorly formed (Fig. 4-22, a-c). In contrast, hepaCAM-
transfected cells were well-spread, displaying abundant centrally located focal 
adhesions (FAs) as well as more peripherally located focal complexes (FXs) and 
nascent FAs as compared to the control cells at this time point (Fig. 4-22, d-f).
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Figure 4-21 hepaCAM changes the phosphorylation
 
of FAK and paxillin. (A)
 
The protein levels of phosphorylated
 




(Y118) and total paxillin
 
in hepaCAM(-) or hepaCAM(+) cells were 
examined by Western blot using respective antibodies. (B) The bar chart shows the 
relative intensity of each protein band. Intensity of the protein band representing 








Figure 4-22 hepaCAM increases the formation of focal adhesions at early stage 
of cell-ECM contact. The cells were spread on fibronectin
 
for 30 min and double 
stained using anti-integrin
 
β1 (green) and anti-paxillin
 
(red) antibodies. Bars, 10 μm. 
Arrow heads: focal adhesions.  
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4.1.7.2.3 hepaCAM promotes the formation of less mature focal contacts at 
later stage of cell-ECM contact  
On the other hand, after spreading on fibronectin for 3 h, the control cells were fully 
spread and developed noticeable mature FAs (Fig. 4-23, g-i). Interestingly, FAs in 
hepaCAM-transfected cells were no longer observable. Instead, fine structures of less 
mature focal contacts (i.e. nascent FAs and FXs) at the periphery and the edge of the 
cells were prominent (Fig. 4-23, j-l), exhibiting features of migrating cells. Thus, 
while hepaCAM is not localized at sites of and not a component of focal contacts, it is 
capable of regulating focal contact assembly in a time dependent manner.  
 
4.1.8 hepaCAM alters the activity of Rho family GTPases 
Rho-family GTPases, including Rho, Rac and Cdc42, play important roles in integrin-
mediated signaling. The classical model suggests that, among the three main Rho 
family GTPases, Rho regulates the assembly of actin stress fibers and FAs; Rac and 
Cdc42 are responsible for the formation of lamellipodia and filopodia, respectively 
(Nobes and Hall, 1995). The activity of GTPases in vector- and hepaCAM-transfected 
cells was examined by Rho/Rac/Cdc42 activation assay (Fig. 4-24). After plating on 
fibronectin for 30 min, hepaCAM-transfected cells expressed a significantly higher 
level of active Rho compared to that in the control cells, consistent with the 
observation that hepaCAM promoted cell spreading. However, the difference in active 
Rho was not obvious at 3 h. On the other hand, the level of active Rac in hepaCAM 
transfectants was significantly lower than the control cells at both time points. No 
significant difference in active Cdc42 was observed between control and hepaCAM-
transfected cells.  
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Figure 4-23 hepaCAM promotes the formation of less mature focal contact at 
later stage of cell-CM contact. The cells were spread on fibronectin
 
for 3 h and 
double stained using anti-integrin
 
β1 (green) and anti-paxillin
 
(red) antibodies. Bars, 















Figure 4-24 hepaCAM alters the activity of Rho family GTPases.  (A)
 
hepaCAM(-) 
and hepaCAM(+) cells were spread on fibronectin
 
for 0.5 or 3 h and evaluated for levels 
of active Rho by GST-Rhotekin
 
pull-down, or for active Rac
 
and Cdc42 by GST-PAK 
pull-down as described in Materials and Methods. (B) The bar charts show the relative 
intensity of each protein band. Intensity of protein band representing control cells at 0.5 h 
was considered as 1. Data represent means ±
 




4.1.9 hepaCAM alters the organization of the actin cytoskeleton 
The actin cytoskeleton provides the mechanical strength driving cell adhesion and 
migration. To examine the effects of hepaCAM on the actin cytoskeleton dynamics, 
the cells were spread on fibronectin for 30 min or 3 h and stained with 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated phalloidin to reveal F-actin. 
The difference in cytoskeletal organization between vector- and hepaCAM-
transfected cells was obvious. While the control cells displayed disorganized actin 
structure (Fig. 4-25, left column), hepaCAM-transfected cells showed robust actin 
stress fibers, forming long bundles of filaments spanning the cytoplasm at 30 min (Fig. 
4-25, right column, arrows). Moreover, highly compact meshworks of actin were 
found at the edge of hepaCAM-transfected cells at 3 h, forming large fan-shaped 
lamellipodia (arrow heads).  
 
4.1.10 hepaCAM induces morphological changes of cells 
The actin cytoskeleton is crucial for sustaining cell morphology. It is noteworthy that 
most of the control cells were polygonal, showing a typical epithelioid morphology. 
In contrast, a significantly higher percentage of hepaCAM-transfected cells displayed 
extended protrusions and polarized lamellipodia, resembling a more migratory, 
fibroblastoid phenotype. Quantification showed a 4-fold increase of cells exhibiting 
fibroblastoid-like morphology in hepaCAM-transfected cells (Fig. 4-26). Such 
morphology is well-associated with high motility (Sehgal, 2010). 
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Figure 4-25 hepaCAM alters the organization of the actin-cytoskeleton. hepaCAM(-) 
and hepaCAM(+) cells were spread on fibronectin
 




to reveal the organization of the actin
 
cytoskeleton. Bars, 10 μm. 
Arrows:actin
 
stress fibers. Arrowheads: lamellipodia. 
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Figure 4-26 hepaCAM induces morphological changes of MCF7 cells. Morphology of  
hepaCAM(-) or hepaCAM(+) cells after spreading on fibronectin
 
for 3 h was 
photographed. Magnification, 320 ×. (B) Bar chart depicts the percentage of cells 
exhibiting fibroblastoid-like morphology (i.e. polarized cell shape with prominent 
lamillipodia
 
at leading edge; arrowheads) quantified by analyzing more than 200 cells 
from 5 randomly selected fields. Data represent means ±
 




4.2 Proteolytic cleavage of hepaCAM 
4.2.1 Characteristics of hepaCAM cleavage 
4.2.1.1 hepaCAM is proteolytically cleaved when re-expressed in MCF7 cells 
The protein structure of hepaCAM has been descirebed in the introduction (Section 
1.5): it is a type-1 transmembrane Ig-like cell adhesion molecule of 416 amino acids, 
consisting of an extracellular domain, a trans-membrane domain, and a cytoplasmic 
domain (Fig. 4-27 A). The entire hepaCAM sequence was cloned into the eukaryotic 
expression vector pcDNA6B/V5-His, with the V5 epitope tagged at the cytoplasmic 
COOH-terminus of hepaCAM, allowing detection of hepaCAM protein with anti-V5 
antibody.  
 
The plasmid containing hepaCAM sequence was transfected into the human breast 
carcinoma cell line MCF7. The molecular mass of the V5-tagged hepaCAM was 
approximately 75 kD (Fig. 4-27 B, lane 2). In addition to the full-length protein of 
hepaCAM, a smaller band of approximately 25 kD was consistently observed, 
suggesting that hepaCAM undergoes a proteolytic cleavage.  
 
4.2.1.2 Identification of a 25-kD species as a hepaCAM cleavage product 
Since the 25-kD species was detected by anti-V5 antibody, this band should represent 
a fragment containing the cytoplasmic COOH-terminus. To verify that the 25-kD 











(A) Sequences of the WT 
and truncated mutants of hepaCAM
 
were cloned into the eukaryotic expression vector 
pcDNA6B/V5-His and transfected
 
into the breast carcinoma cell line MCF7. EX, 




domain.      , signal 
peptitde;      , V5 tag. (B) Protein expression of WT and mutant hepaCAM
 
(hCAM-318 
and hCAM-tail) in MCF7 cells was examined by Western blot using anti-V5 antibody.
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amino acid 318 and 416 was constructed (Fig. 4-27 A). The mutant, designated 
hCAM-318, showed a molecular mass at about 60 kD and an additional band at about 
10 kD (Fig. 4-27 B, lane 3), proving that the 25-kD species was the product of 
hepaCAM cleavage.  
 
4.2.1.3 The cleavage product of hepaCAM contains mainly the cytoplasmic 
domain 
To determine if the 25-kD fragment contains the cytoplasmic domain, we constructed 
another mutant of hepaCAM with the cytoplasmic domain only (residues 260-416), 
designated hCAM-tail (Figure 4-27 A). Interestingly, the cytoplasmic domain alone 
shared a similar molecular mass with the cleaved fragment (Fig. 4-27B, lane 4), 
suggesting that the 25-kD cleavage product contains mainly the cytoplasmic domain 
of hepaCAM.    
 
4.2.1.4 The cleavage product of hepaCAM is membrane tethered 
To determine whether the cleavage product of hepaCAM is dissociated from or 
tethered to the cell membrane, hepaCAM-transfected cells were fractionated into 
cytoplasmic and membrane portions. The purity of each fraction was confirmed by 
the detection of GAPDH (cytosolic marker) and E-cadherin (plasma membrane 
marker). As shown in Figure 4-28, a significant amount of the full-length hepaCAM 
was detected in the membrane fraction and a lower amount of the full-length protein 
appeared in the cytoplasmic fraction. However, the cleavage product of hepaCAM 
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amount in the cytosolic fraction. These results indicated that the cleavage product of 
hepaCAM is membrane tethered. 
 
4.2.2 Mechanisms involved in hepaCAM cleavage 
4.2.2.1 Cleavage of hepaCAM is not dependent on cell density 
Previously we have demonstrated that the subcellular localization of hepaCAM is 
dependent on cell density (Moh et al., 2005a, b). When the cell density is high, 
hepaCAM tends to localize on the plasma membrane, particularly at cell-cell 
boundaries. Whereas when the cells are sparse and well spread, hepaCAM proteins 
are less localized onto cell membranes but more into punctuate intracellular structures.  
Since the cleavage product of hepaCAM is membrane tethered, cell density, a factor 
that regulates the membranous distribution of the protein, is possible to play a role in 
the cleavage process.   
 
To examine how cell density affects hepaCAM cleavage, hepaCAM-transfected cells 
were seeded at decreasing cell densities (100%, 50%, and 25% confluence). The cells 
were then subjected to Western blot analysis. As shown in Figure 4-29, hepaCAM  
displayed identical degrees of cleavage at three different cell densities, suggesting that 
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4.2.2.2 The effects of the phorbol ester PMA on hepaCAM cleavage 
4.2.2.2.1 PMA up-regulates hepaCAM protein expression 
Phorbol esters have been reported to facilitate proteolytic cleavage of numerous cell 
surface proteins, such as E-cadherin (Maretzky et al., 2005) and CD44 (Okamoto et 
al., 1999). To determine if phorbol esters could promote hepaCAM cleavage, the 
effects of phorbol 12-myristate 13-acetate (PMA), one of the most commonly used 
phorbol esters, was examined. hepaCAM-transfected cells were treated with PMA for 
15, 30, 60 or 120 min. As shown in Figure 4-30, PMA up-regulated both the full-
length and the cleavage product of hepaCAM. Quantification of the intensities of the 
protein bands revealed that the ratio of the cleavage product versus the full-length of 
hepaCAM remained constant throughout the time courses, indicating that the degree 
of hepaCAM cleavage was not altered by PMA.   
 
To test if prolonged treatment of PMA would have any effect on hepaCAM cleavage, 
we increased the course of PMA treatment up to 24 h. Cell lysate was harvested every 
4 h and subjected to Western blot analysis. The cleavage of E-cadherin was examined 
as a positive control. Figure 4-31 shows that the cleavage product of E-cadherin was 
increased in a time dependent manner, while the expression level of full-length E-
cadherin was hardly changed throughout the treatment, indicating a significant 
enhancement of the cleavage process of E-cadherin by PMA. PMA also significantly 
increased hepaCAM cleavage product time dependently (Fig 4-32), more prominently 
from 12 h onwards. However, unlike E-cadherin, the full-length of hepaCAM was up-
regulated concurrently. Although the ratio of the cleavage product versus the full-
length of hepaCAM increased consistently from 12 h after PMA treatment (Figure 4-
32 B), such increase was probably due to the saturation of the protein bands 
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and Western blot with anti-V5 antibody. GAPDH served as the loading control. 
Positions of the molecular size markers are shown on the left of
 
the panel. (B) 













cells were treated with PMA for up to 24 h and cells were harvested every 
4 h and subjected to Western blot with anti-E-cadhrin
 
antibody. GAPDH served as 
the loading control. Positions of the molecular size markers are shown on the left of
 
the panel.













Figure 4-32 Long term treatment of PMA up-regulates the protein expression 
of hepaCAM. (A) hepaCAM-transfected
 
cells were treated with PMA for up to 24 h 
and cells were harvested every 4 h and subjected to Western blot
 
with anti-V5 
antibody. GAPDH served as the loading control. Positions of the molecular size 
markers are shown on the left of the panel. (B) Intensities of protein bands were 




S.D., n = 3) are represented in the bar chart. *, P < 0.05.














representing the full-length hepaCAM from 12 h onwards. Therefore, the data are not 
sufficient to support an increase of the cleavage process of hepaCAM. These results 
suggested that prolonged treatment of PMA further up-regulated the protein 
expression of hepaCAM compared to short-term treatment. The effect of PMA on 
hepaCAM cleavage is not obvious even when the treatment is prolonged. 
 
4.2.2.2.2 PMA does not affect hepaCAM at mRNA level 
Subsequently, semi-quantitative RT-PCR was carried out to examine if mRNA 
expression of hepaCAM was altered by PMA. It has been reported that mRNA of the 
intercellular cell adhesion molecule (I-CAM) can be up-regulated by PMA in renal 
cell carcinoma (Tanabe et al., 1997). I-CAM was therefore included as a positive 
control. The results revealed that the mRNA level of I-CAM reached peak 2 h after 
PMA treatment (Fig. 4-33, middle panel), whereas the mRNA level of hepaCAM 
remained unchanged up to 8 h after PMA treatment (Fig. 4-33, upper panel). It was 
noted that hepaCAM protein expression started increasing as early as 2 h upon PMA 
treatment. These results suggested that PMA induces an increase in hepaCAM protein 
expression but does not alter the transcription of hepaCAM.  
 
4.2.2.2.3 PMA-induced protein up-regulation of hepaCAM is dependent on the 
PKC pathway 
PMA is a known activator of PKC. To examine if PMA-enhanced hepaCAM cleavage 
was dependent on PKC activation, hepaCAM-transfected cells were pretreated with 
the specific PKC inhibitor GF109203X prior to the addition of PMA. As 
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cells were treated with PMA for 0, 0.5, 1, 2, 4, or 8 h. The total RNA 
was extracted and RT-PCR was performed with primers specific for hepaCAM
 
or 
I-CAM. GAPDH served as a loading control. (B) Intensities of RNA bands were 
measured and are represented in the bar chart (means 
 




demonstrated, pretreatment of GF109203X abolished the PMA-increased expression 
of hepaCAM (Fig. 4-34). This finding verified that PMA promoted hepaCAM protein 
expression through activation of PKC pathway. 
 
4.2.2.3 PI3 kinase inhibitor suppresses hepaCAM cleavage 
PI3 kinase (PI3K) is an important up-stream regulator of some PKC pathways 
(Morgensztern and McLeod, 2005). To examine if PI3K pathway is involved in 
hepaCAM cleavage, the cells were treated with a PI3K inhibitor wortmannin at 
indicated concentrations (Fig. 4-35). The results showed that the full-length of 
hepaCAM was not changed while the cleavage product was significantly decreased in 
a dose dependent manner, indicating a suppressed cleavage of hepaCAM. The data 
suggested that PI3 kinase plays a role in hepaCAM cleavage. 
 
4.2.2.4 Calcium influx promotes hepaCAM cleavage 
It is known that certain PKC isoforms are Ca2+ dependent (Bootman and Berridge, 
1995). Elevation of intracellular Ca2+ level may activate PKC pathway and 
consequently regulate hepaCAM cleavage. The Ca2+ ionophore ionomycin is one of 
the most widely used reagent to induce calcium influx. The function of ionomycin is 
pH dependent. The optimal pH value for ionomycin to induce proteolysis was 
determined in E-cadherin, a known protein that its cleavage is regulated by calcium 
influx. Figure 4-36 shows that the cleavage of E-cadherin induced by ionomycin was 
enhanced as the pH value increased, reaching maximum at pH 8.5. Thus, subsequent 
experiments in this section were carried out at this pH. 
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Figure 4-34 The PMA-promoted hepaCAM
 
protein expression is dependent on 
PKC. (A) hepaCAM-transfected
 
cells were pre-treated with GF109203X for 2 h 
before treatment of PMA for 16 h. The cells were then lysed
 
and subjected to 
Western blot with anti-V5 antibody. GAPDH served as loading control. Positions of 
the molecular size marker are shown on the left of the panel. (B) Intensities of protein 





S.D., n = 3) are represented in the bar chart. *, P < 0.05.
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were treated with wortmannin
 
at indicated concentrations for 8 h and lysed
 
for 
Western blot with anti-V5 antibody. GAPDH served as the loading control. 
Positions of the molecular size marker are shown on the left of the panel. (B) 
Intensities of protein bands were measured, and the ratios of cleavage product 




S.D., n = 3) are represented in the bar 
chart. *, P < 0.05.
























cleavage is pH dependent. The cells 
were treated with 1 µM ionomycin
 
at indicated pH values for 15 min. The cells were 
then lysed
 
for Western blot with anti-E-cadherin
 
antibody. GAPDH served as the 

















To examine if Ca2+ influx could induce hepaCAM cleavage, the hepaCAM-
transfected cells were treated with the Ca2+ ionophore ionomycin. The results showed 
that ionomycin caused a prominent accumulation of the cleavage product of 
hepaCAM, while the full-length of hepaCAM was correspondingly reduced (Fig. 4-
37). Moreover, when the cells were co-treated with the Ca2+ chelator EDTA, the 
ionomycin-induced hepaCAM cleavage was diminished (Fig. 4-38, lane 4-6). These 
data indicated that the effects of ionomycin on hepaCAM cleavage was dependent on 
the influx of Ca2+ across the plasma membrane followed by the elevation of the 
intracellular Ca2+ level. In addition, the treatment of EDTA alone had no effect on the 
cleavage of hepaCAM (Fig. 4-38, lane 3), suggesting that the extracellular Ca2+ was 
not directly involved in the cleavage of hepaCAM. 
 
One of the consequences of Ca2+ influx is the activation of protein kinase C (PKC) 
(Bootman and Berridge, 1995). To examine the role of PKC in ionomycin-induced 
hepaCAM cleavage, the cells were pretreated with the PKC inhibitor GF109203X 
followed by the treatment with ionomycin. As shown in Figure 4-39, GF109203X had 
no effect on ionomycin-stimulated cleavage of hepaCAM, suggesting that the Ca2+ 
influx-induced cleavage was independent of PKC pathway. 
 
4.2.2.5 Proteasome inhibitors suppress hepaCAM cleavage 
It is common that the cleavage product of a protein is not detectable due to immediate 
degradation mainly through the ubiquitin-proteasome system. For example, the 
cleavage product of CD44 is undetectable without the presence of proteasome 







cleavage. (A) The cells were 
treated with ionomycin
 
at indicated concentrations for 15 min and lysed
 
for Western 
blot with anti-V5 antibody. GAPDH served as the loading control. Positions of the 
molecular size marker are shown on the left of the panel. (B) Intensities of protein 









Figure 4-38 The effect of ionomycin
 
on hepaCAM cleavage is through calcium 




and/or EDTA at indicated 
concentrations for 15 min. The cells were then lysed
 
for Western blot with anti-V5 
antibody. Positions of the molecular size marker are shown on the left of the panel. 
(B) Intensities of protein bands were measured, and the ratios of cleavage product 
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Figure 4-39 Ionomycin-induced hepaCAM
 
cleavage is independent of PKC 
pathway. (A) The cells were pre-treated with 5 µMGF109203X followed by 
incubation with 1 µM ionomycin
 
for 15 min. The cells were then lysed
 
for Western 
blot with anti-V5 antibody. (B) Intensities of protein bands were measured, and
 
the 




S.D., n = 3) are 










hepaCAM was subjected to proteasomal degradation, the cells were treated with a 
proteasome inhibitor MG132. Intriguingly, instead of being accumulated, the cleavage 
product of hepaCAM was significantly reduced after MG132 treatment in a time 
dependent manner (Fig. 4-40). This unexpected result indicated that the cleavage 
process of hepaCAM is rather distinct from that of other CAMs.  
 
It is known that MG132 is not a specific inhibitor of proteasome. In addition to 
proteasome, MG132 has a broad spectrum of inhibitory effects on proteases, 
including β- and γ-secretase  (Steinhilb et al., 2001; Murakami et al., 2003) and the 
cysteine proteases calpain-1 and cathepsin B (Steinhilb et al., 2001). To evaluate the 
involvement of proteasome, hepaCAM-transfected cells were treated with the specific 
proteasome inhibitor clasto-lactacystin β-lactone (mentioned as lactacystin in the 
subsequent text). Figure 4-41 shows that not only MG132 but also lactacystin 
significantly decreased the cleavage product with a slight increase of the full-length of 
hepaCAM. p53 is known to be ubiquitinated. Multiple bands at higher molecular 
weights representing ubiquitinated p53 products were observed after treatment with 
MG132 or lactacystin, confirming the effects of the two proteasome inhibitors. These 
results suggested that the proteasome is indeed involved in hepaCAM cleavage. 
 
4.2.2.6 β- and γ-secretases are not responsible for the MG132-induced 
suppression of hepaCAM cleavage 
Next, to evaluate the possible participation of other enzymes that were inhibited by 
MG132, the cells were treated with β-secretase inhibitor IV or the γ-secretase 
inhibitor DAPT. Interestingly, as shown in Figure 4-42, β-secreatase did not inhibit
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Figure 4-40 MG132 treatment inhibits hepaCAM cleavage. (A) The cells 
were treated with 5 µM MG132 for indicated time points and lysed
 
for Western 
blot with anit-V5 antibody. GAPDH served as the loading control. Positions of 
the molecular size marker are shown on the left of the panel. (B) Intensities of 
































cleavage. (A) The cells were treated with 5 µM MG132 or 2.5 µm lactacystin
 
for 8 h 
and lysed
 
for Western blot with ani-V5 antibody. GAPDH served as the loading 
control. p53 was included as the positive control of inhibition of ubiquitination. 
Positions of the molecular size marker are shown on the left of the panel. (B) 





S.D., n = 3) are represented in the bar chart.
 






















on hepaCAM cleavage. 
(A) The cells were treated with MG132 (5 µM), β-secretase
 
inhibitor IV (10 µM), 
DAPT (10 µM), or pepstatin
 
A methyl ester (20 µM) for 16 h. Cell lysates
 
were 
analyzed by Western blot with anti-V5
 
antibody. GAPDH served as the loading 
control. Positions of the molecular size markers are shown on the left of the panel.
 














 the cleavage of hepaCAM. Conversely, it resulted in an apparent increase of 
hepaCAM cleavage product. In addition, DAPT had no effect on hepaCAM cleavage.  
These results indicated that β- and γ-secretase were not responsible for the MG132-
induced suppression of hepaCAM cleavage.  
 
4.2.2.7 Involvement of cysteine proteases in hepaCAM cleavage 
4.2.2.7.1 Calpin-1 is involved in hepaCAM cleavage 
As MG132 also inhibits cysteine proteases calpain and cathepsin, we finally 
investigated the involvement of these enzymes in hepaCAM cleavage. Two calpain 
inhibitors MDL28170 and calpeptin were used to examine the effects of calpain 
inhibition on hepaCAM cleavage. The results showed that both inhibitors 
significantly reduced the cleavage product and accumulated the full-length of 
hepaCAM (Figure 4-43 and 44). As MCF7 cells are deficient of calpain-2 (Wu et al., 
2006), we assayed for the activation status of calpain-1. In the inactive condition, 
calpain-1 exists as pro-enzyme heterodimer of 80-29 kD, and following Ca2+ binding 
undergoes autolysis to an active 78-18 kD heterodimer (Wang, 2000). Western blot 
analysis revealed the presence of both 78- and 80-kD species of calpain-1 large 
subunit in untreated cells (Fig. 4-45, lane 1), indicating a basal activity of this enzyme. 
Following treatment of MDL28170 and calpeptin, the autolysis of calpain-1 was 
prevented, and a clear accumulation of the 80-kD large subunit was observed (Fig. 4-
45, lanes 2 & 3). These results provided strong evidence that calpain-1 may be 
involved in hepaCAM cleavage. 
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Figure 4-43 The effect of MDL28170 on hepaCAM
 
cleavage. (A) The cells were 





with anti-V5 antibody. GAPDH served as loading control. Positions of the 
molecular size markers are shown on the left of the panel.
 
(B) Intensities of protein 





S.D., n = 3) are represented in the bar chart. *, P < 0.05.

















Figure 4-44 The effect of calpeptin
 
on hepaCAM cleavage. (A) The cells were 




blot with anti-V5 antibody. GAPDH served as loading control. Positions of the 
molecular size markers are shown on the left of the panel. (B) Intensities of 






S.D., n = 3) are represented in the bar chart. *, P < 
0.05.




















Figure 4-45 Caplain-1 is inhibited by MDL28170 and calpeptin. The cells were 
treated with  100 μM MDL28170 or 10 μM calpeptin
 
for 8 h and lysed
 
for Western 
blot with anti-calpain-1 antibody. MDL: MDL28170; CPT: calpeptin.
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We have demonstrated that calcium influx promotes hepaCAM cleavage. Since 
calpain is a calcium dependent enzyme, it is interesting to study if calpain plays any 
role in calcium influx-enhanced hepaCAM cleavage. hepaCAM-transfected cells were 
pretreated with the calpain inhibitor MDL28170 for 2 h followed by the treatment of 
ionomycin for 15 min. As shown in Figure 4-46, MDL28170 significantly suppressed 
ionomycin-triggered increase of hepaCAM cleavage, suggesting that the effects of 
calcium influx on hepaCAM cleavage is partly contributed by calpain-1. 
 
4.2.2.7.2 Cathepsin B is involved in hepaCAM cleavage 
The cysteine proteases cathepsin B and L have been reported to be inhibited by 
MG132 (Malen et al., 2007; Goulet et al., 2004). We showed that two cathepsin 
inhibitors Z-FF-FMK (cathepsin B and L inhibitor) and CA074-Me (cathepsin B 
inhibitor) efficiently decreased hepaCAM cleavage (Fig. 4-47). Taken together, these 
data suggested that calpain-1 and cathepsin B, members of cysteine proteases, were 
involved in the cleavage of hepaCAM.  
 
4.2.3 The cytoplasmic domain plays important roles in hepaCAM functions  
4.2.3.1 The cytoplasmic domain is essential for hepaCAM-mediated cell-ECM   
adhesion 
We have demonstrated that the cleavage product of hepaCAM contains mainly the 
cytoplasmic domain. To investigate if the remaining moiety after cleavage has any 
functional role, a mutant of hepaCAM with the truncation of the entire cytoplasmic 





inhibitor inhibits ionomycin-enhanced hepaCAM cleavage. 
The cells was pre-treated with 100 μM MDL28170 before treatment with 1 μM 
ionomycin
 
for 15 min. The cells were then lysed
 
for Western blot with anti-V5 
antibody. GAPDH served as the loading control. Positions of molecular size 
markers are shown on the left of the panel. 
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Figure 4-47 Effect of cathepsin-B inhibitors on hepaCAM cleavage. (A) The 
cells were treated with 10 μM Z-FF-FMK or 10 μM CA074-Me for 8 h and lysed
 
for Western blot with anti-V5 antibody. GAPDH served as the loading control. 
Positions of molecular size markers are shown on the left of the
 
panel. (B) The 
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Figure 4-48 Generation of cytoplasmic
 
domain-deleted mutant of hepaCAM. 
(A) Schematic representation of WT hepaCAM
 





domain.       , signal 





MCF7 cells was examined by Western blot with anti-V5 antibody.
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this mutant was also used in the study of hepaCAM-integrin β1 interaction. 
hCAM∆tail was stably expressed in MCF7 cells (Fig. 4-48B). The adhesive property 
of MCF7 cells expressing pcDNA6B vector, WT hepaCAM or hCAM∆tail on 
fibronectin was evaluated through cell adhesion assay. Compared to control cells 15% 
and 52%, the spreading of hepaCAM-transfected cells was 35% and 74% (P < 0.05) 
and hCAM∆tail-transfected cells 11% and 47% (P > 0.05), at 30 min and 2 h of 
incubation respectively (Fig. 4-49). These results suggested that when the cytoplasmic 
domain is truncated, hepaCAM loses the ability to promote cell-ECM adhesion. 
 
4.2.3.2  The cytoplasmic domain is critical for hepaCAM-mediated cell migration 
The motility of MCF7 cells expressing pcDNA6B vector, WT hepaCAM or 
hCAM∆tail was assessed by the wound closure assay. Confluent monolayer of cells 
were wounded and allowed to heal. After 24 h of incubation, the wound closure was 
56% by hepaCAM-transfected cells, whereas 32% by hCAM∆tail transfectants, and 
25% by the control cells.  
 
After 48 h, the wound closure reached 86% by hepaCAM transfectants, 59% by 
hCAM∆tail transfectants and 51% by the control cells (Fig. 4-50). hepaCAM 
transfectants displayed the fastest wound closure (P < 0.05) and the closure rate of 
hCAM∆tail transfectants was comparable (P > 0.05) to that of the control. Moreover, 
at 3 h, hepaCAM-transfected cells at the edge of the wound showed noticeable cell 
protrusions (Fig. 4-50, middle panel, arrowheads), which marked the start of cell 
migration. When the cytoplasmic domain was deleted, such protrusions were not 
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Figure 4-49 Effects of cytoplasmic
 
domain truncation on hepaCAM-mediated 
cell-ECM adhesion.
 





were spread on fibronectin-coated surface. After 30 min or 2h, the 
morphology of cells was observed and microscopic pictures were taken. 200 ×
 
magnification. (B) Cells exhibiting spread morphology was counted in five 
randomly selected fields and the percentages were calculated and
 
presented in the 
bar chart (means 
 







Figure 4-50 Effects of cytoplasmic
 
domain truncation on hepaCAM-mediated 









were scratched and allowed to grow. Microscopic 
pictures were taken after 24 h and 48 h.  100× magnification. (B) Percentages of 
wound closure at 48 h are represented in the bar chart. (means 
 











observed (Fig. 4-51, right panel), similar to the control cells (Fig. 4-51, left panel). 
These results indicated that when the cytoplasmic domain is cleaved, hepaCAM is not 
able to enhance cell motility. 
 
4.2.3.3 The cytoplasmic domain plays a key role in the growth inhibitory effects 
of    hepaCAM 
4.2.3.3.1 Colony formation 
To study the role of the cytoplasmic domain in cell growth mediated by hepaCAM, 
MCF7 cells were transfected with either WT hepaCAM or hCAM∆tail. Cells 
transfected with the pcDNA6B vector served as the control. After 12 days of 
antibiotic selection, the colonies formed were stained with crystal violet for 
observation (Fig. 4-52). Compared to the vector control, expression of hepaCAM 
strongly reduced both the number and the size of cell colonies. The expression of 
hCAM∆tail less significantly inhibited colony formation.  
 
4.2.3.3.2 Cell proliferation 
Furthermore, the growth rate of cells transfected with pcDNA6B control, WT 
hepaCAM or hCAM∆tail was determined by MTT cell proliferation assay (Fig. 4-53). 
Compared to that of the control cells, the growth rate of hepaCAM transfectants was 
significantly slower (P < 0.05) on day 5. However, hCAM∆tail did not clearly inhibit 
the proliferation of MCF7 cells. Together with the colony formation results, these data 
implied that the inhibitory effect of hepaCAM on cell growth is diminished when the 






cells displayed protrusions during migration. 
In the same wound closure assay as in Fig. 4-49, microscopic photos of cell 
morphology at the edge of wound were taken 3 h after the scratches were made. 
Arrowheads:
 
cell protrusions. 320 × magnification. 
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Figure 4-52 The effect of cytoplasmic
 
truncation on the hepaCAM-mediated 
suppression on colony formation. (A) MCF7 cells were transfected
 
with 
pcDNA6B vecotr, hepaCAM or hCAM∆tail
 
and selected in 10 μg/ml blasticidin
 
for 12 days. The colonies formed were stained with 1% crystal violet (upper row). 
Microscopic photos of the average cell density in a stained colony were taken at 100 
× magnification (lower row). (B) The number and size of colonies (means ± S.D., 





Figure 4-53 The effect of cotyplasmic
 
domain truncation on the hepaCAM-
 
mediated inhibition on cell proliferation.
 
Growth rate of cells transfected
 
with 
pcDNA6B vector, hepaCAM or hCAM∆tail
 
was monitored by MTT assay for 5 
days. Data represent means ± SD of three experiments performed in triplicates. *, 
P < 0.05. 
*
0        1         2         3        4        5   (Days)
*
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4.2.3.3.3 Cell cycle 
To study if the antiproliferative effect of hepaCAM was a consequence of cell cycle 
arrest, flow cytometry was carried out to determine the cell cycle distribution of the 
cells. Intriguingly, hepaCAM transfectants displayed a unique cell cycle profile in that 
83% of the cell population was accumulated in the G2/M phase (Fig. 4-54), indicating 
a significant G2/M cell cycle arrest. However, MCF7 cells expressing hCAM∆tail 
displayed a cell cycle profile similar to that of the control cells, suggesting that the 
cytoplasmic domain was critical for the regulation of cell cycle by hepaCAM. 
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Figure 4-54 The effects of cytoplasmic
 
domain truncation on the hepaCAM-
 
mediated cell cycle regulation. Cell cycle distribution of cells transfected
 
with 
pcDNA6B vecor, hepaCAM or hCAM∆tail
 
was determined by flow cytometry. 
Percentages of cells in each phase (means ± S. D., n = 3) are represented in the 



































CHAPTER 5    DISCUSSION 
5.1 Connection between hepaCAM and the integrin-dependent signaling 
5.1.1 hepaCAM accelerates initial cell attachment 
Cell adhesion is generally comprised of four steps: cell attachment to ECM substrate, 
cell spreading, focal contact assembly and cytoskeletal re-organization (Adams, 1997). 
The first step - initial cell attachment - is distinct from the following processes as this 
step is entirely dependent on the direct interaction between the adhesion molecules - 
in most cases integrins - and the ECM proteins. An increase in initial cell attachment 
is usually associated with an enhanced integrin affinity. The data on cell attachment 
provided the evidence that hepaCAM changes the affinity of the integrin(s) which 
mediate the cell attachment to the fibronectin substrate.  
 
5.1.2 hepaCAM increases cell spreading   
Following cell attachment to an ECM substrate is cell spreading, which involves more 
complicated signaling events leading to focal contact  assembly and cytoskeletal re-
organization (Adams, 1997). The cell spreading results suggested that besides altering 
the activity of integrins, hepaCAM also affects the downstream signaling following 
cell-ECM contact.  
 
5.1.3  hepaCAM promotes both the velocity and directionality of cell migration 
Cell migration can be conceptualized as a cyclic process. The first step is to extend 
cell protrusions in the direction of migration. The protrusions can be large, broad 
lamellipodia or spike-like filopodia. These structures are driven by actin 
polymerization and stabilized by adherence to the ECM substrate via various CAMs. 
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These adhesions serve as traction sites during migration as the cell moves forward 
over them. They are disassembled at the cell rear to allow the cell to detach 
(Huttenlocher et al., 1995). Thus, modulation in cell adhesion would result in changes 
in migration. Time-lapse microscopy enabled us to observe the behaviors of 
individual cells during migration and showed an overall more mobile phenotype of 
hepaCAM-transfected cells. The enhanced velocity of hepaCAM-transfected cells 
was consistent with our previous results on wound healing (Moh et al., 2005a, b, 
2008). In addition, hepaCAM also enhanced the directionality of migration. 
Conceptually, directional cell migration has two sources: intrinsic cell directionality 
and external regulation. Intrinsic directionality is observed when cells respond to a 
non-directional motogenic signal, such as the uniform application of platelet-derived 
growth factor (PDGF) that triggers the basic motility machinery in the absence of any 
external guiding factor. Random migration occurs when a cell has low intrinsic 
directionality. If the motogenic stimulus is presented as an external gradient or with 
another external guidance cue, the cell then exhibits induced directionality (Petrie et 
al., 2009). The hepaCAM-induced directionality was intrinsic as no triggers such as 
chemical gradient or chemoattractant were included in the study. 
 
5.1.4 Physical association between hepaCAM and integrin β1 
We showed that hepaCAM physically associated with integrin β1 through cis 
conformation. Whether this interaction is direct or indirect is not clear. The in vitro 
translated hepaCAM and integrin β1 were not co-immunoprecipitated, suggesting an 
indirect interaction. However, it is noteworthy that the translated hepaCAM had a 
molecular size of about 50 kD, smaller than the 75 kD size of the exogenously 
expressed hepaCAM in MCF7 cells. This is probably due to the lack of 
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posttranslational modification of hepaCAM. It has been shown that different 
glycosylation on the extracellular domain of hepaCAM leads to distinct profiles of 
interacting partners (Gaudry et al, 2008), suggesting the importance of 
posttranslational modification in protein-protein interaction; therefore the results from 
the in vitro translated proteins may not reflect the true property of hepaCAM. The 
interaction between integrin β1 and native hepaCAM remains to be further 
investigated.  
 
5.1.5 Truncated mutants of hepaCAM 
When exogenously expressed in MCF7 cells, WT hepaCAM, hCAM∆1st Ig, 
hCAM∆2ndIg and hCAM∆tail were expressed at different protein levels that 
hCAM∆tail displayed the highest expression and hCAM∆1st Ig showed the lowest 
expression. Because the protein expression was examined in stable cell clones, the 
difference should not be derived from different transfection efficiencies of each 
plasmid but rather a reflection of the role of each domain in regulation of hepaCAM 
protein expression. Several clones of each mutant were examined to ensure that the 
difference was not derived from different sites of chromosomal integration. The 1st Ig 
domain seems to be important to the expression and/or stabilization of hepaCAM 
protein as deletion of this domain results in significantly reduced protein level. 
Whereas the cytoplasmic domain appears to be inhibitory to the expression and/or 
stabilization of hepaCAM since hCAM∆tail has an increased expression compared to 
the WT. In addition, both hCAM∆2ndIg and hCAM∆tail showed double bands with at 
least one band of a smeared shape, while hCAM∆1st Ig had a distinct single band. The 
smearing effect of a protein band is usually due to posttranslational modification such 
as glycosylation (Vina-Vilaseca et al., 2011). We have previously shown that 
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hepaCAM undergoes N-linked glycosylation (Moh et al., 2005b). In another 
experiment, when deglycosylated with PNGase, all three truncated mutants shifted to 
a smaller molecular size and displayed single bands, suggesting that N-linked 
glycosylation is retained in all truncated mutants, thus glycosylation occurs on both 1st 
and 2nd Ig domains.  
 
Subcellular localization of the truncated mutants showed that, in line with the Western 
blot results, hCAM∆1st Ig showed a relatively low staining intensity compared to the 
WT and other mutants. In addition, hCAM∆1st Ig was the only mutant that lost the 
localization on the plasma membrane. Thus the 1st Ig domain is not only important for 
maintaining the level of protein expression, but also critical for the localization of 
hepaCAM on the plasma membrane. It has been demonstrated that the subcellular 
localization of SIRT1 is changed by increased protein stability (Byles et al., 2011), 
and the sbucellular localization of E2F-1 protein affects its stability (Ivanova et al., 
2006). It is possible that the expression level of hepaCAM and the subcellular 
localization are also interrelated.  
 
5.1.6 Integrin β1 associates with all truncated mutants of hepaCAM 
The immunoprecipitation data showed that all truncated mutants tested, including 
hCAM∆1st Ig, hCAM∆2ndIg and hCAM∆tail, were able to co-immunoprecipitate with 
integrin β1, suggesting that none of the domains – the 1st Ig, the 2nd Ig and the 
cytoplasmic domain - is indispensible for the interaction between hepaCAM and 
integrin β1. It is possible that multiple binding sites are involved in the interaction and 
deletion of any single domain does not affect the overall interaction between the two 
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proteins. Another possibility is that hepaCAM indirectly interacts with integrin β1 
through other proteins. If the truncated mutant remains associated with other binding 
partners, the association with integrin β1 would be retained.  
 
It was mentioned that the interaction between WT hepaCAM and integrin β1 could 
only be detected when the cells were treated with the crosslinking agent DSP, 
indicating a weak interaction. Similarly, DSP was required to co-immunoprecipitate 
integrin β1 with hCAM∆1st Ig and hCAM∆2ndIg. However, the co-
immunoprecipitation of integrin β1 and hCAM∆tail was easily detected without 
crosslinking, suggesting that the interaction between integrin β1 and hCAM∆tail is 
rather firm. Therefore, the presence of the cytoplasmic domain of hepaCAM may 
destabilize the interaction with integrin β1. Alternatively, the high expression of 
hCAM∆tail may contribute to the more stable interaction with integrin β1. 
 
Previously we have shown that only intact hepaCAM is able to interact with F-actin.  
The truncated mutants - hCAM∆1st Ig, hCAM∆2ndIg and hCAM∆tail - all lost this 
interaction (Moh et al., 2008). It is well known that integrins link with the actin 
cytoskeleton via complex adaptor proteins (Blystone, 2004). Since deletion of any of 
the domains would lead to the loss of hepaCAM-actin interaction, it is not likely that 






5.1.7 The interacting integrin α subunit is not identified  
Integrins are heterodimeric receptors composed of α and β subunits. We have 
identified integrin β1 as an interacting partner of hepaCAM; in theory, hepaCAM 
should also be associated with an α subunit that pairs with integrin β1 to form the 
functional heterodimer. However, the major integrin α subunits in MCF7 cells - α2, 
α3, and αV- were not shown to interact with hepaCAM. There may be several reasons: 
experimentally, the antibodies used might not be suitable for immunoprecipitation; or 
the condition of immunoprecipitation was not optimized. Alternatively, it is possible 
that the interacting α subunit is not among the ones we have tested. It might be a less 
represented integrin α that is expressed at a low level in MCF7 cells.  
 
5.1.8 hepaCAM up-regulates the protein expression and total activity of 
integrin β1 
Integrins remain inactive under normal condition and are converted to an active form 
upon ligand binding, i.e. binding to ECM substrates. The activation process 
drastically enhances the affinity of integrins, leading to cell attachment and spreading 
(Calderwood, 2004). An accelerated initial cell attachment is usually associated with 
increased affinity of surface integrins towards the binding substrate. Our data 
demonstrated that the expression of integrin β1, more importantly the active form (i.e. 
with high affinity towards ECM), was significantly up-regulated in hepaCAM-
transfected cells. This finding is particularly important as it provides the basis for 




There are two possibilities that the total activity of integrin β1 is increased: 1) through 
the increase of the overall protein expression; or 2) by affecting regulators of integrin 
activation. The first possibility was supported by the experimental data that the 
increase of total protein expression of integrin β1 in hepaCAM-transfected cells was 
almost proportional to the increase of the active form. The increase of integrin β1 was 
not at the mRNA level, suggesting that hepaCAM probably affects posttranscriptional 
regulation or translation of integrin β1. How hepaCAM alters these processes remain 
to be further explored. The second possibility was tested by examining the effects of 
hepaCAM on talin. Talin has long been considered as the sole regulator of integrin 
activation (Moser et al., 2009). It directly binds to the cytoplasmic domain of integrin 
and causes conformational changes that lead to increased affinity. However, neither 
the expression of talin was changed by hepaCAM nor was there any interaction 
between talin and hepaCAM. Thus the increased active form of integrin β1 by 
hepaCAM is likely to be independent of talin. Nevertheless, kindlins have recently 
been emerged as a class of novel regulators of integrin activity (Moser et al., 2008). 
The interaction between hepaCAM and kindlins is worth further investigation.  
 
5.1.9 hepaCAM  regulates focal contact assembly 
Following cell attachment to an ECM substrate is cell spreading, which involves focal 
contact  assembly and cytoskeletal re-organization (Adams, 1997). Focal contacts are 
complex structures consisting of multiple protein complexes that transduce bi-
directional mechanical and chemical signals between extracellular and intracellular 
compartments (Bershadsky et al., 2003; Chen et al., 2004; Geiger et al., 2001). The 
stability and size of focal contacts increase in a complicated process of maturation. 
144 
 
Nascent FAs (focal points) and FXs are newly formed focal contacts that are 
distributed at the extreme edge or periphery of the cells; whereas FAs are mature, 
large and stable focal contacts that are predominantly located at central area of the 
cells (Wozniak et al., 2004). Our results showed that hepaCAM was not localized at 
the sites of focal contacts, therefore not a component of the complex focal contact 
structures. However, the assembly of focal contacts in hepaCAM-transfected cells at 
different time points differed significantly from that of the control, suggesting a 
regulatory role of hepaCAM in focal contact assembly. Many cell types exhibit a 
biphasic relationship between cell migration speed and substratum adhesiveness 
(Huttenlocher et al., 1996; Gobin and West, 2002), with maximum migration rates at 
intermediate adhesiveness where cells can both efficiently form adhesions at the cell 
front and release adhesive contacts at the cell rear (DiMilla et al., 1993; Huttenlocher 
et al., 1995). It has been postulated that molecules strengthening cell-ECM adhesion 
would result in decreased cell migration due to “adhesive brake” (Shi et al., 2007). 
However, the optimal adhesiveness for cell migration is strictly dependent on cell 
type and the ECM substratum. A striking feature of hepaCAM is that it exhibits 
temporal regulation on focal contact assembly. At early time points of cell-ECM 
contact, hepaCAM promoted the formation of stable FAs allowing cells to adhere to 
the substratum efficiently. However at later time points, while the control cells 
developed mature FAs and establish stable cell-ECM adhesion, focal contacts in 
hepaCAM-expressing cells were predominantly localized at cell periphery, where less 
mature focal contacts (i.e. nascent FAs and FXs) with high turnover were formed, 
favoring cell migration. Therefore, the increased cell velocity of hepaCAM-
transfected cells during migration could be due to the subsequent decreased cell-ECM 
adhesiveness as a result of the regulation of focal contact assembly. 
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Moreover, the Western blot results of phosphorylated FAK and paxillin were in line 
with the immunofluorescence images. The data showed an overall increase of focal 
contact assembly in hepaCAM-transfected cells compared to the control cells at early 
time points and decrease at later time points. However, the difference, although 
statistically significant (~10%, P < 0.05), was not as drastic as what was observed 
from the confocal photographs. This is probably due to the changes in focal contact 
assembly often occurring at confined areas, e.g. the periphery of cells. In other word, 
it is rather a “local” than a “global” effect; therefore only a relatively small fraction of 
focal contact proteins are involved. When performing Western blot analysis, proteins 
from the whole cell lysate are examined, and the difference between small fractions of 
proteins would be masked.   
 
5.1.10 hepaCAM alters the activity of Rho and Rac 
The Rho family of small GTPases play crucial roles in various cellular behaviors 
including cell adhesion, migration, and morphology (Evers et al., 2000). The classic 
model of Rho family GTPases assigns specific roles to each of the members, e.g. Rho 
regulates the assembly of actin stress fibers and FAs, and is important for cell 
spreading and contractility; Rac and Cdc42 are responsible for the formation of 
lamellipodia and filopodia, respectively, and are crucial for cell polarization and 
migration (Nobes and Hall, 1995). However, many lines of evidence support an 
intrinsically more complicated picture of Rho family GTPases signaling, which 
sometimes contradicts with the classic model. For example, in contrast to the clear 
effects of the overexpression of double negative (DN) mutants, cells in which Rac1 
(Wheeler et al., 2006) or Cdc42 (Czuchra et al., 2005) have been genetically ablated 
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can still protrude lamellipodia and produce filopodia, and only display very mild 
defects in cell migration. This suggests that the contributions of Rac1 and Cdc42 to 
the process of cell migration are much more subtle than we initially thought. Another 
example is the finding that RhoA is linked not only to the generation of contractility, 
but also to the regulation of microtubule stabilization at the leading edge during 
directional cell migration (Bartolini and Gundersen, 2009; Palazzo et al., 2001). 
Rather than involving Rho kinase, this specific RhoA function requires stabilization 
of microtubules through the effector mDia. RhoA therefore most probably performs 
different functions at the front and at the back of migrating cells, undoubtedly through 
selective interactions with different downstream effectors. A recent study using 
advanced imaging techniques provide new insight into the inter-relationships of Rho 
family GTPases: multiple Rho GTPase signaling modules crosstalk in a spatial and 
temporal manner to regulate specific morphogenetic events of the cells (Pertz, 2010).  
 
Our data showed that Rho activity was increased by hepaCAM at an early stage of 
cell adhesion, consistent with the increased cell spreading and actin stress fiber 
formation. Furthermore, Rac activity was reduced in hepaCAM-transfected cells at 
both stages. This finding is particularly interesting. As shown in the results with cell 
morphologies, hepaCAM-transfected cells often display prominent protrusions and 
large lamellipodia, which in the classic model are usually associated with a higher 
activity of Rac. Thus our results were contradictory to the classic conception. 
However, it has been recently reported that Rac is closely related to the directionality 
of intrinsic cell migration. Even a very small decrease in Rac activity can switch 
random migration to directional (Pankov et al., 2005). Therefore, the reduced Rac 
activity in hepaCAM-transfected cells may underlie the directional mode of migration 
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induced by hepaCAM. The mechanism of how hepaCAM decreases the activity of 
Rac is unclear. Immunoprecipitation has been performed and no interaction between 
hepaCAM and Rac is identified. Whether hepaCAM affects the factors that control 
the GDP-GTP cycle, such as GEFs and GAPs, is worth further investigation.  
 
5.1.11 hepaCAM alters the organization of the actin cytoskeleton and cell   
morphology 
One of the most striking features of hepaCAM-transfected cells is the differed cell 
morphology. Cell morphology/shape is determined by the cytoskeleton, which 
includes three subclasses: microfilaments (actin), microtubules and intermediate 
filaments. Among the three, microfilaments are the most dynamic and play a central 
role in cell shape and motility (Pollard and Cooper, 2009). They give mechanical 
support to cells and hardwire the cytoplasm with the surroundings to support signal 
transduction. Different cell types have different cell shape and cytoskeleton structures. 
The majority of MCF7 cells display a disorganized structure of actin cytoskeleton (Li 
et al., 2008). However the expression of hepaCAM induced the formation of actin 
stress fibers at early time points and lamellpodia at later time points of cell-ECM 
contact. Previously we reported the direct interaction between hepaCAM and F-actin 
(Moh et al., 2009). Working in a complex with integrin β1 and actin, hepaCAM may 
serve as a modulator that conveys and relays extracellular signals to the intracellular 
cytoskeletal machinery. Whether the altered organization of the actin cytoskeleton is 
the consequence of altered integrin activity or induced by hepaCAM directly needs to 
be further explored. Furthermore, decreased Rac activity has also been documented to 
be associated with a more fibroblastoid and migratory phenotype (Evers et al., 2000). 
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Thus, our data suggested that hepaCAM, possibly in collaboration with other 
signaling components, regulates Rho- and Rac-mediated effects on the actin 
cytoskeleton, leading to the observed motile cell morphology with extended 
protrusions and polarized lamellipodia. The effects of hepaCAM on microtubules and 
intermediate filaments, the other two types of cytoskeleton that support cell shape, 
will be explored in future studies.  
 
5.1.12 hepaCAM, a tumor suppressor or oncogene? 
This study uncovers a novel connection between hepaCAM and integrin-dependent 
signaling and provides the molecular basis for the hepaCAM-mediated cell-ECM 
interaction. On the other hand, it also raises some intriguing questions. Previously we 
have demonstrated that hepaCAM is commonly suppressed in human cancers and 
exhibits suppressive effects on cell growth, showing properties of a tumor suppressor 
(Moh et al., 2005b). Here we show that hepaCAM time dependently promotes both 
cell-ECM adhesion and migration, which under most circumstances have opposing 
effects on cancer. While firm adhesion would lower the rate of extravasations and 
prevent cancer cell invasion, increased cell motility would promote metastasis. 
Moreover, as a putative tumor suppressor, how can the inhibitory effect of hepaCAM 
on cell growth be integrated with the promoting role in cell motility? 
 
Many CAMs function as tumor suppressors, e.g. E-cadherin (Watabe et al., 1994), 
CADM1 (Yageta et al., 2002; Heller et al., 2007), and integrin α7 (Ren et al., 2007). 
When introduced into cancer cells, these molecules not only suppress cell growth but 
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also retard cell motility. However, evidence is currently emerging to support the 
contradictory roles of CAMs that both inhibit cell growth and promote cell motility 
when restored in cancer cells. In addition to hepaCAM, the Ig superfamily 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is 
implicated in functioning as a tumor suppressor and as a metastasis promoter. The 
characteristics and functions of CEACAM1 have been demonstrated in individual 
reports. CEACAM1 is frequently downregulated or dysregulated in multiple human 
tumors (Riethdorf et al., 1997; Neumaier et al., 1993), and is capable of suppressing 
cell growth and inducing apoptosis (Nittka et al., 2008). Ebrahimnejad et al. (2004) 
demonstrated that exogenous expression of CEACAM1 enhances melanoma cell 
invasion and migration; and this enhanced motility can be reverted by anti-
CEACAM1 antibodies. The ability of CEACAM1 to co-stimulate tumor suppression 
and invasion was finally established by Liu et al. (2007) in restricting thyroid cancer 
growth but promoting invasiveness. Introduction of CEACAM1 into CEACAM1-
deficient thyroid cancer cells results in G1/S phase cell cycle arrest accompanied by 
elevated p21 expression and diminished Rb phosphorylation. Overexpression of 
CEACAM1 also increases cell-ECM adhesion but promotes cell migration and tumor 
invasiveness. In xenografted mice, CEACAM1 expression results in reduced tumor 
growth and increased tumor invasiveness. Conversely, silencing of endogenous 
CEACAM 1 accelerates tumor growth and suppresses invasiveness (Li et al., 2007). 
 
The paradox of the contradictory roles that hepaCAM and CEACAM1 possess on 
cancer development has not been resolved. The expression levels, the types and stages 
of tumors, as well as other intracellular or extracelluar cues could be important factors 
that affect their functions. In a previous study, we showed that hepaCAM inhibits the 
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growth rate and suppresses wound healing of the glioblastoma U373 cells (Lee et al., 
2009), suggesting that hepaCAM may have different functions in different cell types, 
probably due to distinct  interacting partners and local environment. In addition, 
temporal regulation of protein expression may be a plausible hypothesis to explain the 
paradox. It has been shown that the expression of CEACAM1 is spatially and 
temporally regulated during different stages of malignancies (Riethdorf et al., 1997; 
Liu et al., 2007). A model that covers all stages of cancer development would be 
helpful to reveal if the expression of hepaCAM is differentially regulated during 




 5.2 The proteolytic cleavage of hepaCAM 
5.2.1 hepaCAM undergoes a proteolytic cleavage when expressed in MCF7 
cells 
In this study, we demonstrated for the first time that hepaCAM undergoes a 
proteolytic cleavage when exogenously expressed in MCF7 cells. It would be 
valuable to study the cleavage pattern of endogenously expressed hepaCAM. 
However, as we have reported previously, this gene is frequently lost in diverse 
human tumors (Mon et al., 2005a, b, 2008). Moreover, the cytoplasmic domain of 
hepaCAM is highly phosphorylated (Moh et al., 2005b), making it difficult to 
generate antibodies against the cytoplasmic region. Therefore, our research was based 
on transfection studies with the hepaCAM deficient cell line MCF7 and detection of 
the V5 tagged hepaCAM by an anti-V5 antibody. Similar transfection studies have 
been performed in other cell lines such as HeLa, HepG2, HCT116, NIH3T3, etc., and 
the exogenously expressed hepaCAM constantly shows an additional band at a 
smaller size than the expected full-length, suggesting that the proteolytic cleavage is a 
common process for hepaCAM in multiple cell types. 
 
5.2.2 The cleavage product of hepaCAM contains mainly the cytoplasmic 
domain 
By comparing the molecular sizes we concluded that the cleavage product of 
hepaCAM contains mainly the cytoplasmic domain. For many transmembrane 
proteins, the extracellular portion is often responsible for ligand binding or receiving 
other extracellular signals, while the cytoplasmic domain is usually involved in 
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intracellular signal transduction that leads to functional changes.  Although the exact 
function of the cytoplasmic domain of hepaCAM is not clear, several motifs related to 
protein-protein interaction or posttranslational modifications have been identified in 
the cytoplasmic region. The PROSITE and PSORT II programs predicted a proline-
rich region (residues 325-385) with 6 SH3-binding domains, a nuclear localization 
signal (residues 265-271), a prokaryotic membrane lipoprotein lipid attachment site 
(residues 252-262), a tyrosine sulfation site (274-288), a casein kinase II 
phosphorylation sites (residues 331-334), and four protein kinase C phosphorylation 
sites (residues 266-268, 357-359, 371-373, 394-396). 
 
5.2.3 The cleavage product of hepaCAM is membrane tethered 
Subcellular fractionation showed that while the full length hepaCAM was found in 
both cytosol and membrane fractions, the cleavage product of hepaCAM was 
predominantly detected in membrane fraction, indicating that this fragment is 
membrane tethered. Since the fractionation kit does not differentiate plasma 
membrane from membranes of intracellular organelles, it is possible that the 
cleavage process occurs on both types of membranes. It is well known that the 
Golgi complex is an important site for proteolytic processing. Most secretory 
proteins and some plasma-membrane proteins undergo post-Golgi proteolytic 
cleavages that yield the mature, active proteins. Generally, proteolytic maturation 
occurs in secretory or transport vesicles carrying proteins from the trans-Golgi 
network to the cell surface (Xu and Shields, 1993; Sambamurti et al., 2006). 
The membrane tethering property also indicates that the cleavage product contains at 
least part of the transmembrane domain. This is in line with the Western blot result 
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that the size of the cleavage product was slightly larger than the cytoplasmic domain 
alone. Therefore the site of cleavage is probably around the transmembrane domain 
approaching the extracellular side.  
 
5.2.4 PMA has no effect on hepaCAM cleavage 
PMA is a phorbol ester and an activator of PKC. The effects of PMA on PKC result 
from its similarity to one of the natural activators of classic PKC isoforms, 
diacylglycerol. PMA has been widely documented to stimulate cleavage of cell 
surface proteins (Hooper et al., 1997; Werb and Yan, 1998). Exposure to PMA up to 2 
h only up-regulated the total protein expression of hepaCAM. Prolonged treatment 
with PMA up to 24 h further enhanced the expression level and resulted in an increase 
of the ratio between the cleavage product over the full-length of hepaCAM. However, 
this increase was probably due to the saturation of the full-length protein at later time 
points. It has been reported that the effects of PMA on proteolytic processing is rapid 
(Clemens et al., 1992); therefore we concluded that PMA has no effect on hepaCAM 
cleavage.  
 
PMA is able to increase the expression of many proteins primarily due to the 
activation of PKC (Kohutek et al., 2009; Jolly-Tornetta and Wolf, 2000). Using a 
PKC inhibitor GF109203X, we showed that the PMA-induced up-regulation of 
hepaCAM is indeed through PKC. However, when examining the mRNA level, 
unlike I-CAM which showed an obvious increase, the expression of hepaCAM was 
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not changed. Probably PMA affects hepaCAM expression through an unconventional 
pathway at posttranscription level.  
 
5.2.5  Calcium influx promotes hepaCAM cleavage 
Ionomycin enhances Ca2+ influx by stimulating store-regulated cation entry at the 
plasma membrane (Morgan and Jacob, 1994). We showed that Ca2+ influx induced by 
ionomycin promoted hepaCAM cleavage. Such effect could be diminished by the 
Ca2+ chelator EDTA, supporting the role of Ca2+ influx in inducing hepaCAM 
cleavage. Elevation in intracellular Ca2+ concentration is known to activate PKC 
(Bootman and Berridge, 1995). However, the PKC inhibitor GF109203X failed to 
exhibit any inhibitory effect on ionomycin-induced hepaCAM cleavage, implying that 
the downstream PKC activation is not required for activation of this Ca2+ influx-
initiated pathway.  
 
Increased intracellular Ca2+ level is known to transduce diverse intracellular signaling 
(Berridge et al., 1998). The proteolytic cleavage of other cell surface molecules, 
including E-cadherin, TGF-α, c-kit receptor and HB-EGF, can also be enhanced by 
extracellular calcium influx (Ito et al., 1999; Pandiella et al., 1992; Yee et al., 1993; 
Dethlefsen et al., 1998). These data suggested the existence of a common pathway for 
the induction of proteolytic cleavage through calcium mobility, though the underlying 





5.2.6 Proteasome is involved in hepaCAM cleavage 
Proteasome inhibitors are usually used to stabilize cleavage products that are 
subjected to proteasome degradation. For example, the residual membrane-tethered 
cleavage product of E-cadherin could not be detectable by Western blot analysis. 
However, it becomes apparent by treatment with the proteasome inhibitor MG132 (Ito 
et al, 1999). Unlike other proteins, treatment of MG132 did not reveal any putative 
degraded protein of hepaCAM, nor was the cleavage product increased. In contrast, 
the cleavage was inhibited, suggesting an involvement of proteasome in hepaCAM 
cleavage. It is of note that the main function of proteasome is to degrade unneeded 
proteins by non-specific proteolysis (Rivett, 1993). On the other hand, recent studies 
have shown that proteasome can cleave its substrate in a specific manner. Sorokin et 
al. (2005) have demonstrated that Y-box-binding protein 1 (YB-1) undergoes a 
limited proteolysis by the 20S proteasome (Sorokin et al., 2005). Other examples of 
proteins undergoing limited proteasomal cleavage include the translation initiation 
factors eIF4G and eIF3a (Baugh and Pilipenko, 2004). The mechanism of hepaCAM 
cleavage mediated by proteasome remains unknown.  
 
5.2.7 The secretases are not involved in hepaCAM cleavage   
Besides proteasome, MG132 exhibits inhibitory effects on other enzymes, including 
β-, γ-secretases and cysteine proteases (Seinhilb et al., 2001; De Strooper et al., 1999; 
Tsubuki et al., 1996). Secretases are enzymes that cleave transmembrane proteins. 
The most well known example is the effects of secretases act on the amyloid 
precursor protein (APP) that cleaves the protein into three fragments. Sequential 
cleavage by β-secretase (BACE) and γ-secretase produces the amyloid-β peptide 
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fragment that aggregates into clumps called "plaques" in the brains of Alzheimer's 
disease patients. If α-secretase acts on APP first instead of BACE, no amyloid-β is 
formed because α-secretase recognizes a target protein sequence closer to the cell 
surface than BACE (Vassar et al., 1999). 
It has been reported that MG132 inhibits the cleavage of Notch-1 by γ-secretase (De 
Strooper et al., 1999). Brown et al (2000) showed that γ-secretase is involved in the 
regulated intramembranous proteolysis (RIP) (Brown et al., 2000). RIP cleaves only 
type-1 transmembrane proteins (Struhl et al., 2000) and does not depend on sequence 
recognition (Xia and Wolfe, 2003). We have shown that hepaCAM is a type-1 
transmembrane protein (Moh et al., 2005a), offering a clue that hepaCAM may be a 
substrate of RIP. However, γ-secretase inhibitor failed to suppress hepaCAM cleavage, 
ruling out that hepaCAM is an RIP substrate. It has also been shown that MG132 
blocks maturation of the APP Swedish mutant by preventing its cleavage by β-
secretase (Steinhilb et al., 2001). Interestingly, the inhibitor of β-secretase leads to an 
accumulation of the cleavage product, suggesting that, as a negative regulator, β-
secretase may indirectly be involved in hepaCAM cleavage.  
 
5.2.8 Cysteine proteases are involved in hepaCAM cleavage 
Cysteine proteases are a family of enzymes that have a common mechanism involving 
a nucleophilic cysteine thiol in a catalytic triad. Among members of cysteine protease 
family, calpains as well as cathepsin B and L can be inhibited by MG132 (Tsubuki et 
al., 1996). Calpains belong to the family of calcium-dempendent, non-lysosomal 
cysteine proteases expressed ubiquitously in mammals and many other organisms. 
The calcium-dependent activity, intracellular localization, along with the limited, 
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specific proteolysis on its substrates, highlight calpain’s role as a regulatory, rather 
than a digestive protease (Ohno et al., 1994). Two isoforms of calpains, calpain 1 and 
calpain 2 (or µ-calpain and m-calpain), have been identified. They have different 
calcium requirements, i.e. micro- and nearly millimolar concentrations of Ca2+ within 
the cell, respectively (Glass et al., 2002). Cathepsin B and L are two the most 
abundant lysosomal proteases, having concentrations as high as 1 mM (Turk et al., 
2000). They are ubiquitous enzymes whose functions have been proposed to extend 
beyond the confines of the lysosomes. For example, in addition to being localized in 
the lysosome, cathepsin B (or alternatively spliced variants of cathepsin B) can be 
found on the surface or in the periplasmic space of tumor cells (Roshy et al., 2003; 
Sinha et al., 2001; Sameni et al., 1995). Using inhibitors of calpain and cathepsin, we 
showed the possible involvement of calpain-1 and cathepsin B in hepaCAM cleavage. 
It is noteworthy that the function of calpain is dependent on calcium and calcium 
influx is able to increase calpain activity (Huang and Wang, 2001). Thus an elevated 
calpain activity may partly explain the promoting effect of ionomycin on hepaCAM 
cleavage.  
 
5.2.9 Multiple pathways are involved in hepaCAM cleavage 
Collectively, we have demonstrated several pathways that regulate hepaCAM 
cleavage. The existence of multiple pathways for the regulation of proteolytic 
cleavage have been shown in other membrane proteins, including transforming 
growth factor-α (Pandiella and Masague, 1991), Kit ligand (Huang et al., 1992), c-kit 
receptor (Yee et al., 1993), and heparin-binding epidermal growth factor (Dethlefsen 
et al., 1998). Each pathway of hepaCAM cleavage may be responsible for a particular 
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intracellular or extracellular signal, so that hepaCAM could respond to a variety of 
stimulations in a complex physiological or pathological environment. 
 
5.2.10 Functional significance of hepaCAM cleavage 
An interesting feature of hepaCAM cleavage is that it gives rise to a cleavage product 
containing mainly the cytoplasmic domain. We have previously demonstrated that 
hepaCAM exhibits anti-proliferative effects on cancer cell lines and promotes cell- 
ECM interactions (Moh et al., 2005a, b, 2008). Here we have further shown that 
truncation of the cytoplasmic domain largely reduced the effects of hepaCAM on cell-
ECM adhesion and cell motility. Moreover, the mutant hepaCAM without the 
cytoplasmic domain has lost the inhibitory effects on cell growth and failed to induce 
G2/M cell cycle arrest. The importance of the cytoplasmic domain has been 
emphasized in the functional regulation of transmembrane proteins. Alterations of 
several CAMs at the cytoplasmic region have led to dysfunction of the proteins. One 
such CAM is the tumor suppressor in lung cancer 1 (TSLC1), which harbors the 4.1 
ezrin/radixin/moesin (FERM) and PSD-95/Dig/ZO-1 (PDZ)-interacting motif in the 
cytoplasmic domain. Deletion of these motifs abrogates tumor suppressor activity of 
TSLC1 (Mao et al., 2003). Another example is CD44. Using the truncation mutants 
lacking part of the cytoplasmic domain, Jiang et al. (2002) have shown that the CD44 
cytoplasmic domain is required for hyaluronan binding, pericellular matrix assembly, 
and receptor-mediated endocytosis in COS-7 cells (Jiang et al., 2002). Our findings 
on hepaCAM reiterate the importance of the cytoplasmic domain in the functions of 






Proteolytic cleavage is often viewed as a regulatory switch that can have activating or 
inactivating effects on protein functions. For example, some pro-enzymes (such as 
caspases) need to be cleaved and converted to their active forms (Cohen, 1997); on 
the other hand, cleavage causes the inactivation of many proteins or removal of 
receptors from cell surface (Gearing and Newman, 1993).  It is noteworthy that the 
cytoplasmic truncated mutant of hepaCAM has impaired function in cell-ECM 
interaction and cell growth control, implying that the cleavage of hepaCAM has a 
negative regulatory effect on its own activity. To further prove this hypothesis, a 
mutant that is resistant to cleavage would be helpful. This would require the 
identification of the cleavage site and mutagenesis of the residues that are essential for 
the cleavage process of hepaCAM.  
 
CHAPTER 6 CONCLUSION 
6.1 Conclusion 
The present study investigates the properties of the novel gene hepaCAM, focusing on 
the connection between hepaCAM and the integrin-dependent signaling as well as the 
mechanisms and significance of its proteolytic cleavage.  
 
When re-expressed in MCF7 cells, hepaCAM accelerates the initial cell adhesion and 
spreading on a fibronectin substrate. Moreover, both the velocity and directionality of 
cell migration are enhanced by the expression of hepaCAM. Through biochemical 
studies, hepaCAM is shown to be physically associated with integrin β1, the most 
highly expressed integrin in MCF7 cells; furthermore, hepaCAM up-regulates the 
protein expression of integrin β1 as well as its active form in a talin-independent 
manner. Interestingly, hepaCAM regulates the assembly of the focal contacts, the sites 
where the cells make connections to the ECM substrate, time dependently. The unique 
regulation allows the cells to adhere to the ECM substrate quickly and adapts to a 
migration mode in an efficient way. In addition, hepaCAM alters the activity of Rho 
family GTPases, which are important mediators in integrin-dependent signaling. 
While the increased Rho activity is associated with accelerated cell spreading, the 
decreased Rac activity is well connected to the enhanced directionality of cell 
migration induced by hepaCAM. At last, the altered signaling mediated by hepaCAM 





hepaCAM undergoes a proteolytic cleavage at around the transmembrane region 
when re-expressed in MCF7 cells. This cleavage generates a 25-kD cleavage product 
containing mainly the cytoplasmic domain of hepaCAM. The phorbol ester phorbol 
12-myristate 13-acetate (PMA), which is a cleavage inducer of many transmembrane 
proteins, has no effect on hepaCAM cleavage. However, the cleavage is promoted by 
the Ca2+ ionophore ionomycin and the effect could be diminished by the Ca2+ chelator 
ethylenediaminetetraacetic acid (EDTA). In addition, inhibitors of proteasome and 
cysteine proteases strongly suppress the cleavage of hepaCAM, indicating the 
involvement of proteasome, calpain-1 and cathepsin B. Furthermore, functions of 
hepaCAM are significantly impaired when the cytoplasmic domain is cleaved. The 
cytoplasmic truncated mutant of hepaCAM fails to promote cell-ECM adhesion and 
migration, and loses the inhibitory effects on cell growth, suggesting a regulatory role 
of the cleavage in hepaCAM functions. 
 
In conclusion, the data presented to date shed light on the molecular basis of 
hepaCAM-mediated cell-ECM interaction and a possible mechanism that hepaCAM 
employs to regulate its function. Further exploration along these directions may 
provide insight into the role of hepaCAM in cellular behaviors, cancer progression 
and the application of hepaCAM in diagnosis and/or treatment of human cancers or 







6.2 Future work 
The work presented in this thesis has laid the foundation for further studies. Along 
with the interesting findings obtained for hepaCAM, several lines of research may be 
pursued.  
 
The dual functions of hepaCAM in suppressing cell growth and promoting cell 
motility seem contradictory as hepaCAM has been identified as a putative tumor 
suppressor. Profiling the expression of hepaCAM in tumors at different stages may 
reveal how hepaCAM is differentially regulated during the progression of cancer.  
 
The functional significance of hepaCAM cleavage can be further explored. It will be 
particularly interesting to identify the site of hepaCAM cleavage and generate a 
mutant resistant to cleavage by site-directed mutagenesis. Such mutant may help us to 
examine the functions of hepaCAM when the cleavage mechanism is disabled and to 
better understand the role of the cleavage in regulating hepaCAM functions.   
 
It will be of great significance to explore the in vivo role of hepaCAM in development 
and physiology. Genetic knock-out along with tissue-specific analysis may give 
evidence how hepaCAM contributes to certain physiological processes. In addition, 
proteomics-based technologies may facilitate to identify the protein networks that 
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100 mg/ml in H2O 
 
Kanamycin 30 mg/ml in H2O 
 
Blasticidin 10 mg/ml in H2O  
 
All water-soluble antibiotics were filter-sterilized. 
 
 






0.5g Yeast Extract 
1% NaCl 
 
LB agar 1% Tryptone 




CaCl2 solution 60 mM CaCl2, 
15% Glycerol 
10 mM PIPES [piperazine-N,N’-bis(2-hydroxypropane-
sulfonic acid)] 
Adjust pH to 7.0 
 
0.1 M IPTG 1.2 g IPTG (isopropyl-beta-D-thiogalactopyranoside) in 50 
ml of H2O 
X-gal (2 ml) 100 mg X-Gal (5-bromo-4-chloro-3-indolyl--D-








Solutions for agarose gel electrophoresis and DNA purification from gel 
Solution Concentration 
 
1× TAE buffer 
 
40 mM Tris 
20 mM Acetic acid 
1 mM EDTA 
Adjust pH to 7.8 
 
6× Loading dye  0.25% (w/v) Xylene Cyanol FF   
15% (w/v) Ficoll 400  
0.25% (w/v) Bromophenol Blue  
 
3 M sodium acetate Dissolve 123g of sodium acetate in 500 ml of H2O 




Solutions for immunocytochemistry 
Solution Concentration 
 
1× PBS (1 liter) 
 
 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 • 7H2O, 0.24 g 
KH2PO4  
Adjust pH to 7.2 
 
3.7% Paraformaldehyde (50 ml) Add 1.85 g of paraformaldehyde into 40 ml of 1X PBS. 
Warm to dissolve. Add 5M NaOH dropwise until solution 
clears. Adjust pH to 7.4 and increase volume to 50 ml. Filter-
sterilize and aliquot. Store at -20C 
 
 





50 mM Tris pH8.0 
150 mM NaCl 







Solutions for Western blot 
Solution Concentration 
 
2× Laemmli sample buffer 
 




0.01% bromophenol blue 
 




0.05% Bromophenol blue 
10% separating gel (10 ml)  2.72 ml H2O, 3.75 ml Tris-HCl pH 8.8, 3.33 ml 30% 
acrylamide/bis solution (29:1; Biorad), 100 l 10% SDS, 100 
l 10% APS (ammonium persulfate), 4 l TEMED 
4% stacking gel (4 ml)  2.75 ml H2O, 0.5 ml Tris-HCl pH 6.8, 0.67 ml 30% 
acrylamide/bis solution, 40 l 10% SDS, 40 l 10% APS, 4 
l TEMED 
 
1× SDS-PAGE running buffer 25 mM Tris-HCl 
0.2 M Glycine 
0.1% SDS 
Adjust pH to 8.3 
 
Stripping buffer 25 mM Glycine 
Adjust pH to 2.0  
1% SDS 
 
Towbin transfer buffer 25 mM Tris 
192 mM Glycine 
20% v/v Methanol 
Adjust pH to 8.3 
 
10× TBS 0.2M Tris base 
1.37M NaCl 
Adjust pH to 7.6 
 
1× TBS 20 mM Tris base 
137 mM NaCl 
Adjust pH to 7.6 
 
1× TBS/T  
  
0.1% Tween-20 in 1× TBS 
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